

Biological Macromolecules: Bioactivity and Biomedical Applications 1st Edition

Editor by [Amit Kumar Nayak](#), [Amal Kumar Dhara](#), [Dilipkumar Pal](#)

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2022 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-323-85759-8

For Information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>

Publisher: Andre G. Wolff
Acquisitions Editor: Michelle Fisher
Editorial Project Manager: Barbara Makinster
Production Project Manager: Swapna Srinivasan
Cover Designer: Matthew Limbert

Typeset by MPS Limited, Chennai, India



Preface

The scope of this book, entitled *Biological Macromolecules: Bioactivity and Biomedical Applications*, is the coverage and review of recent trends and applications of biological macromolecules, such as carbohydrates, lipids, proteins, peptides, and nucleic acids in biomedicines, drug delivery, growth factors delivery, nutrients and nucleic acids delivery, cell encapsulation, enzyme mobilization, and tissue engineering.

The mysteries of life lie in biological macromolecules. A large volume of biological macromolecules is obtained from different biological origins such as plants, algae, fungi, animals, and microbial sources. Biological macromolecules exhibit some significant and favorable advantages over synthetic macromolecules, such as sustainable and economic production, biocompatibility, biodegradability, and improved bioavailability. In recent years, a plethora of biological macromolecules (carbohydrates, lipids, proteins, peptides, and nucleic acids) has been used in the biomedical and healthcare fields. They showed varieties of bioactivities such as antioxidant, anticancer, antidiabetic, antimicrobial, immunomodulatory activities on the central nervous system, and gastrointestinal activity. The other biomedical applications include drug delivery, growth factors delivery, nutrients and nucleic acids delivery, cell encapsulation, enzyme mobilization, and tissue engineering. The structure–property relationship is also an important aspect for a thorough understanding of the bioactivity of biological macromolecules.

This book, containing 4 sections and 26 chapters, provides a systematic insight into the inclusive discussions on bioactivity and biomedical applications of different biological macromolecules. We are glad to see that many authors across the globe accepted our invitation and contributed valued chapters for this book, covering a wide spectrum of fields. A concise account of the contents of each chapter has been described to provide a glimpse of the book to the potential readers of various fields.

The topics in the book (in order of preference) include the following: *Biological Macromolecules: Sources, Properties, and functions* (Chapter 1)—this chapter describes sources physicochemical properties, bioactivity and biomedical applications of different biological macromolecules concisely; *Structure–Activity Relationship of Biological Macromolecules* (Chapter 2)—this chapter aims to provide an overview of the structural features influencing the bioactivities of biological macromolecules, namely L-amino acid oxidases, lysostaphin, and metallo- β -lactamase-such as lactonase and chitosan; *The Importance of Biological Macromolecules in Biomedicine* (Chapter 3)—this chapter highlights the therapeutic aspects of macromolecules and the medicinal use of biological macromolecules against various diseases and ailments; *Modification Techniques for Carbohydrate Macromolecules* (Chapter 4)—this chapter characteristically abridges the significant developments of the last five to ten years and discusses critically in the area of modification of carbohydrates macromolecules;

Biological Macromolecules as Nutraceuticals (Chapter 5)—this chapter aims to demonstrate some recent knowledge regarding the nutraceutical and biological activities of the macromolecules of biological origin, as well as some frontier applications of these in healthcare; *Biological Macromolecules as Antioxidants* (Chapter 6)—this chapter highlights the potential applications of biological macromolecules as antioxidants to scavenge reactive oxygen species and control oxidative stress, which leads to various pathogenesis; *Biological Macromolecules as Antimicrobial Agents* (Chapter 7)—the chapter describes the antimicrobial activity of biological macromolecules (chitosan, cellulose, alginate, gelatin, collagen, and keratin) and also, comprehensively elucidates their applications in addressing challenges associated with drug delivery, wound dressing, food packaging, and so on; *Biological Macromolecules From Algae and Their Antimicrobial Applications* (Chapter 8)—this chapter provides an overview of bioactive macromolecules and their antimicrobial activities with particular reference to algal sources; *Biological Macromolecules Acting on Central Nervous System* (Chapter 9)—in this chapter, the role of biological macromolecules on central nervous system and their critical role in downregulation after the various neurological disorders have been discussed; *Biological Macromolecules as Antidiabetic Agents* (Chapter 10)—this chapter is an overview of different types of biological macromolecules and their applications as potential antidiabetic agents and also, highlights the advantages, limitations and future perspectives of biological macromolecules as antidiabetic agents; *Biological Macromolecules as Anticancer Agents* (Chapter 11)—this chapter presents the extraction of macromolecules such as carbohydrate, proteins, lipids, and nucleic acid (miRNAs) from different biological sources, such as plants, animal, algae and fungi. The various mechanisms by which the macromolecules exhibit their anticancer activity have been

discussed briefly along with several assays done to evaluate cytotoxicity of the macromolecules against various cancers such as lung cancer, breast cancer, cervical cancer, and colon cancer. *Biological Macromolecules as Immunomodulators* (Chapter 12)—this topic focuses on the potential modulations of immune response of biomacromolecules (three major classes of compounds: lipids, proteins and polysaccharides); *Biological Macromolecules Acting on Gastrointestinal Systems* (Chapter 13)—this chapter describes the role of biological macromolecules for the management of gastrointestinal system and related disorders; *Synthetic Macromolecules With Biological Activity* (Chapter 14)—this chapter describes some classes of synthetic macromolecules with biological activity that have a great importance on the human comfort and health, including antimicrobial polymers, antioxidant polymers, and polymeric sequestrants; *Biological Macromolecules in Drug Delivery* (Chapter 15)—this chapter focuses on the advancements in the uses of various biological macromolecules in drug delivery applications; *Biological macromolecules in tissue engineering* (Chapter 16)—this chapter provides an overview on the important role of natural-derived biomaterials (alginate, chitosan, carrageenan, fucoidan, ulvan, collagen, and gelatin) combining with ceramic biomaterials for bone tissue construction; *Biological Macromolecules for Drug Delivery in Tissue Engineering* (Chapter 17)—This chapter is focused on the preparation and physicochemical characterization of engineered biomaterials, based on biological macromolecules (polysaccharides and proteins), as scaffolds which are capable of supporting physiological activities of cells, but also can act as drug delivery systems for tissue engineering and wound healing; *Biological Macromolecules for Growth Factor Delivery* (Chapter 18)—this chapter discusses the fabrication of synthetic and natural macromolecules, sometimes combined with other mineral or metallic compounds for growth factor delivery; *Biological*

Macromolecules for Growth Factor Delivery in Bone Regeneration (Chapter 19)—this chapter describes the process of bone tissue regeneration in healing injuries and arthritic conditions, introduces the main ideas through the scope of allogeneous and autogeneos transplantation and demonstrates the role of growth factors in these processes; *Biological Macromolecules for Nutrients Delivery* (Chapter 20)—This chapter focuses on the types of nutrients that need to be delivered, the biological macromolecules that can be used to construct edible delivery systems, the most common delivery systems currently used for this purpose, and some of the major challenges that must be addressed in the future; *Biological Macromolecules for Nucleic Acid Delivery* (Chapter 21)—this chapter describes the nonviral nucleic acid delivery systems made up of biological macromolecules, such as peptides, lipids, and carbohydrates and also gives an introduction on the history and structure of nucleic acids; *Biological Macromolecules in Cell Encapsulation* (Chapter 22)—this chapter aims to review the most examined, most promising and recently proposed biopolymers that are used in tissue engineering scaffolds, and to highlight their main properties, drawbacks, fields of applications and fabrication technologies in order to provide readers with important guidelines for selecting appropriate scaffold biomaterials; *Biological Macromolecules for Enzyme Immobilization* (Chapter 23)—this chapter provides a broad overview of properties and the applications of various naturally occurring biopolymers, that is, chitosan, chitin, agarose, alginates, cellulose, gelatin, dextran, carrageenan, pectin and xanthan gum for their applications in enzyme immobilization with recent literature studies indicating biopolymer-based support material development and their utilization to make biocatalysts with desired stability and catalytic functionalities; *Carbohydrates for Enzyme Inhibition and Their Use as Target Molecules for the Interference of Diseases* (Chapter 24)—this chapter describes the study of a widespread group of enzymes and the

inhibition of these enzymes constitutes an interesting and novel strategy to approach new therapies against numerous diseases; *Current Challenging Issues of Biological Macromolecules in Biomedicine* (Chapter 25)—this chapter provides information on recent innovations in various biomaterials, engineered from macromolecules ranging from drug delivery, cancer therapies, tissue engineering, bioprinting and wound healing; *Future Perspectives of Biological Macromolecules in Biomedicine* (Chapter 26)—this chapter discusses the impact of the combination of nanotechnology and chronobiology in personalized cancer treatment.

We sincerely acknowledge the valuable contribution of the distinguished authors and convey our sincere thanks. This book could not have been published without the cooperation of Barbara Makinster, Editorial Project Manager. We wish to express our cordial gratitude to Elsevier Inc., Michelle Fisher (Acquisition Editor), and other editorial staff for their invaluable supports in organizing the intelligent editing of the book. We also gratefully acknowledge all the permissions we received for reproducing the copyright materials from different sources. Finally, we cannot overlook the sacrifices and supports from our family members during the preparation of the current book. All our friends, colleagues, and students who have helped in the process of editing this book deserve our great appreciation. Contributing authors, the publishers, and we, the editors, will be extremely happy if our endeavor fulfills the needs of the academicians, researchers, students, pharmaceutical experts, biomedicine experts, and formulators.

**Amit Kumar Nayak¹, Amal Kumar Dhara²
and Dilipkumar Pal³**

¹Department of Pharmaceutics, Seemanta Institute of Pharmaceutical Sciences, Jharpokharia, India

²Department of Pharmacy, Contai Polytechnic, Govt. of West Bengal, Contai, India ³Department of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India

Contents

List of contributors xiii

Preface xix

I

Background

1. Biological macromolecules: sources, properties, and functions

AMAL KUMAR DHARA AND AMIT KUMAR NAYAK

- 1.1 Introduction 3
- 1.2 Carbohydrates 4
 - 1.2.1 Monosaccharides 5
 - 1.2.2 Oligosaccharides 5
 - 1.2.3 Polysaccharides 5
- 1.3 Lipids 9
 - 1.3.1 Simple lipids 10
 - 1.3.2 Compound or conjugate lipids 10
 - 1.3.3 Derived lipids 10
- 1.4 Proteins 11
 - 1.4.1 Simple proteins 12
 - 1.4.2 Conjugated proteins 13
 - 1.4.3 Derived proteins 13
- 1.5 Nucleic acids 14
 - 1.5.1 Nucleotides 15
 - 1.5.2 Nucleosides 15
 - 1.5.3 DNA 15
 - 1.5.4 RNA 16
- 1.6 Conclusion 18
- References 18

2. Structure–activity relationship of biological macromolecules

AURELIE SARAH MOK TSZE CHUNG, YONG KIAT TEO,
WAI TENG CHENG AND JOASH BAN LEE TAN

- 2.1 Introduction 23
- 2.2 Enzymes as bioactive proteins 24
 - 2.2.1 L-amino acid oxidases 25

- 2.2.2 Lysostaphin 28
- 2.2.3 Metallo- β -lactamase-like lactonase 32
- 2.3 Chitosan as a bioactive polysaccharide 36
 - 2.3.1 Relationship of chitosan physicochemical property and its bioactivity 37
 - 2.3.2 Bioactivity of chitosan with modified functional group 41
- 2.4 Conclusion 43
- References 43

3. The importance of biological macromolecules in biomedicine

AHMED OLATUNDE, OMAR BAHATTAB, ABDUR RAUF,
NAVEED MUHAMMAD, YAHYA S. AL-AWTHAN,
TABUSSAM TUFAIL, MUHAMMAD IMRAN AND
MOHAMMAD S. MUBARAK

- 3.1 Introduction 53
- 3.2 Biological macromolecules in biomedicine and therapies 53
- 3.3 Carbohydrates 54
 - 3.3.1 Therapeutics based on carbohydrates 55
- 3.4 Peptides 56
 - 3.4.1 Therapeutics based on peptides 57
- 3.5 Proteins 58
 - 3.5.1 Therapeutics based on proteins (proteins and monoclonal antibodies) 58
- 3.6 Lipids 60
 - 3.6.1 Drug delivery-based on lipids 60
- 3.7 Nucleic acids and oligonucleotides 61
 - 3.7.1 Therapeutics based on oligonucleotides 61
- 3.8 Synthesis of macromolecules 63
- 3.9 Biomedicine 64
- 3.10 Conclusions 65
- References 65

4. Modification techniques for carbohydrate macromolecules

AJAY VASUDEO RANE, DEEPTI YADAV
AND KRISHNAN KANNY

- 4.1 Introduction 69

- 4.2 Cellulose 69
- 4.3 Hemicelluloses 71
- 4.4 Lignin 72
- 4.5 Chitin and chitosan 72
- 4.6 Modification of carbohydrate biological macromolecules 73
- References 86

II

Bioactivity

5. Biological macromolecules as nutraceuticals

IRERI ALEJANDRA CARBAJAL-VALENZUELA,
 NUVIA MARINA APOLONIO–HERNANDEZ,
 DIANA VANESA GUTIERREZ-CHAVEZ,
 BEATRIZ GONZÁLEZ-ARIAS,
 ALEJANDRA JIMENEZ-HERNANDEZ,
 IRINEO TORRES-PACHECO, ENRIQUE RICO-GARCÍA,
 ANA ANGELICA FERREGRINO-PÉREZ
 AND RAMÓN GERARDO GUEVARA-GONZÁLEZ

- 5.1 History of the applications of nutraceutical compounds in health care 97
- 5.2 Alkaloids 99
 - 5.2.1 Caffeine 99
 - 5.2.2 Capsaicin 101
 - 5.2.3 Theobromine 101
- 5.3 Phenolic compounds 102
 - 5.3.1 Curcumin 102
 - 5.3.2 Resveratrol 103
 - 5.3.3 Quercetin 103
 - 5.3.4 Anthocyanins 103
 - 5.3.5 Luteolin 104
 - 5.3.6 Naringenin 104
 - 5.3.7 Catechins 104
- 5.4 Terpenes 105
 - 5.4.1 Lycopene 105
 - 5.4.2 β -Carotene 105
 - 5.4.3 Lutein 106
 - 5.4.4 Zeaxanthin 107
- 5.5 Future views 107
- 5.6 Proteins and peptides with biological activity of medical interest 107
- 5.7 Nucleic acids and their nutraceutical properties used in biomedicine 112
 - 5.7.1 Nucleic acids overview 112
 - 5.7.2 Perspectives 119
- 5.8 Introduction of lipids 119

- 5.8.1 Polyunsaturated fatty acids 120
- 5.8.2 The role of Omega-3 PUFAs in some disorders 121
- 5.9 The potential use of bioactive lipids in cancer stem cells and coronavirus disease (COVID-19) 123
 - 5.9.1 Bioactive lipids in cancer 123
 - 5.9.2 Bioactive lipids in COVID-19 123
- 5.10 Carbohydrates as nutraceuticals 124
 - 5.10.1 Brief overview of carbohydrates 124
 - 5.10.2 Role of polysaccharides in extracellular membrane 124
 - 5.10.3 Immunostimulatory effect of carbohydrates 125
 - 5.10.4 Carbohydrates from plants with nutraceutical activity 125
 - 5.10.5 Cellulose and hemicellulose 125
 - 5.10.6 Animal derived carbohydrates with nutraceutical activity 126
 - 5.10.7 Heparin 126
 - 5.10.8 Hyaluronic acid 127
 - 5.10.9 Chitosan and chitin 127
 - 5.10.10 Carbohydrates with nutraceutical activity from microorganisms 128
 - 5.10.11 Alginate 128
 - 5.10.12 Dextran 128
 - 5.10.13 *Bacillus striatum* polysaccharide 128
- 5.11 Credit 129
- References 129

6. Biological macromolecules as antioxidants

T. MADHUJITH, N.E. WEDAMULLA AND D.A.S. GAMAGE

- 6.1 Introduction 139
- 6.2 Types and sources of biological macromolecules 141
 - 6.2.1 Polysaccharides 141
 - 6.2.2 Proteins 149
 - 6.2.3 Other antioxidative macromolecules 152
- 6.3 Macromolecules as antioxidants 152
 - 6.3.1 Polysaccharides as antioxidants 152
 - 6.3.2 Proteins as antioxidants 155
 - 6.3.3 Nonextractable polyphenols as antioxidants 156
- 6.4 Applications 156
 - 6.4.1 Food-based applications 156
 - 6.4.2 Other applications 158
- 6.5 Limitations of biological macromolecules 158
- 6.6 Future trends 159
- References 159

7. Biological macromolecules as antimicrobial agents

MD. SHAHRUZZAMAN, SHAFIUL HOSSAIN,
TANVIR AHMED, SUMAYA F. KABIR,
MD. MINHAJUL ISLAM, ASHIQUR RAHMAN,
MD. SAZEDUL ISLAM, SABRINA SULTANA AND
MOHAMMED MIZANUR RAHMAN

- 7.1 Introduction 165
- 7.2 Classification of biological macromolecule 167
 - 7.2.1 Carbohydrate 167
 - 7.2.2 Protein 169
 - 7.2.3 Lipid 170
 - 7.2.4 Nucleic acid 171
- 7.3 Antimicrobial activity of biological macromolecules 172
 - 7.3.1 Polysaccharides 172
 - 7.3.2 Proteins 175
 - 7.3.3 Fatty acids 177
- 7.4 Antimicrobial activity of macromolecule composites 180
 - 7.4.1 Chitosan-alginate 180
 - 7.4.2 Gelatin-chitosan 181
 - 7.4.3 Keratin-chitosan 182
 - 7.4.4 Collagen-alginate 183
 - 7.4.5 Chitosan-cellulose 184
 - 7.4.6 Lactoferrin-Oleic Acid 185
- 7.5 Nanotechnology based antimicrobial macromolecule 185
 - 7.5.1 Chitosan based nanocomposite 185
 - 7.5.2 Alginate-based nanocomposite 187
 - 7.5.3 Cellulose based nanocomposite 187
 - 7.5.4 Gelatin based nanocomposite 189
 - 7.5.5 Collagen based nanocomposite 190
 - 7.5.6 Keratin-based nanoparticle 190
 - 7.5.7 Oleic acid based nanoparticle 190
- 7.6 Applications 190
 - 7.6.1 Food packaging 190
 - 7.6.2 Drug delivery 191
 - 7.6.3 Wound dressing 192
- 7.7 Conclusion 193
- References 193

8. Biological macromolecules from algae and their antimicrobial applications

NATANAMURUGARAJ GOVINDAN,
GAANTY PRAGAS MANIAM, MOHD HASBI AB. RAHIM,
AHMAD ZIAD SULAIMAN AND AZILAH AJIT

- 8.1 Introduction 203
- 8.2 Bioactive macromolecules 203

- 8.2.1 Terpenoids 203
- 8.2.2 Steroids 206
- 8.2.3 Phenolics 207
- 8.2.4 Alkaloids 208
- 8.2.5 Polysaccharides 208
- 8.2.6 Peptides 209
- 8.2.7 Polyketide 210
- 8.2.8 Polyunsaturated fatty acids 210

8.3 Conclusion 213

References 213

9. Biological macromolecules acting on central nervous system

DILIPKUMAR PAL AND KHUSHBOO RAJ

- 9.1 Introduction 219
 - 9.1.1 Proteins 219
 - 9.1.2 Cell cycle proteins 220
 - 9.1.3 Homer/vesl proteins 220
 - 9.1.4 Central fatty hypothesis 222
 - 9.1.5 Carbohydrates 222
 - 9.1.6 Role of carbohydrates on nervous system 223
 - 9.1.7 In sensory organs 223
 - 9.1.8 Glycans 223
 - 9.1.9 Role of glycan in neural development 224
 - 9.1.10 Lipids 224
 - 9.1.11 Role of cPLA2 in cerebral ischemia 225
 - 9.1.12 In the case of neurodegenerative diseases 225
 - 9.1.13 Lipid peroxidation 225
- 9.2 Conclusion 226
- References 226

10. Biological macromolecules as antidiabetic agents

JAISON JEEVANANDAM, CALEB ACQUAH
AND MICHAEL K. DANQUAH

- 10.1 Introduction 229
- 10.2 Types of biological macromolecules 230
- 10.3 Biological macromolecules 232
 - 10.3.1 Carbohydrates 232
 - 10.3.2 Lipids 233
 - 10.3.3 Proteins 235
 - 10.3.4 Nucleic acids 237
- 10.4 Advantages, limitations, and future perspectives 238

10.5 Conclusion 238

References 239

11. Biological macromolecules as anticancer agents

HIMJA TIWARI, HARSHAL DESHMUKH,
NILESH SHIRISH WAGH AND JAYA LAKKAKULA

11.1 Introduction 243

11.2 Biological macromolecules for cancer therapy 244

11.2.1 Carbohydrates 244

11.2.2 Proteins and nucleic acid 258

11.2.3 Lipids 262

11.3 Conclusion 269

References 269

12. Biological macromolecules as immunomodulators

EDUARDO COSTA, MANUELA MACHADO,
MANUELA PINTADO AND SARA SILVA

12.1 Introduction 273

12.2 Immunomodulation 274

12.3 Immunomodulation, biomolecules, and applications 274

12.4 Polysaccharides 275

12.4.1 Immunomodulatory polysaccharides 275

12.4.2 Gut microbiota modulation 277

12.5 Lipids 277

12.5.1 Immunomodulatory effect of lipids 278

12.6 Proteins 280

12.6.1 Known immunomodulatory proteins 280

Acknowledgments 282

References 282

13. Biological macromolecules acting on gastrointestinal systems

DILIPKUMAR PAL AND SUPRIYO SAHA

13.1 Introduction 289

13.2 Role of carbohydrates in gastrointestinal system 289

13.3 Role of proteins in gastrointestinal system 295

13.4 Role of fatty acids in gastrointestinal system 298

13.5 Role of nucleic acids in gastrointestinal system 300

13.6 Conclusion 301

References 302

14. Synthetic macromolecules with biological activity

STEFANIA RACOVITA, MARCEL POPA,
LEONARD IONUT ATANASE AND SILVIA VASILIU

14.1 Introduction 305

14.2 Synthetic macromolecules with antimicrobial activity 306

14.2.1 History of antimicrobial agents and antimicrobial polymers 307

14.2.2 Classification of antimicrobial polymers 308

14.2.3 Preparation routes for antimicrobial polymers 309

14.2.4 Factors affecting the antimicrobial activity 311

14.2.5 Synthetic macromolecules with antibacterial activity 313

14.2.6 Synthetic macromolecules with antiviral activity 317

14.2.7 Synthetic macromolecules with antifungal activity 318

14.2.8 Synthetic macromolecules with antiparasitic activity 319

14.3 Synthetic macromolecules with antioxidant activity 320

14.4 Polymer sequestrants 324

14.5 Conclusions 328

References 328

Further reading 335

III

Functional applications

15. Biological macromolecules in drug delivery

AMIT KUMAR NAYAK, MD SAQUIB HASNAIN,
ANINDITA BEHERA, AMAL KUMAR DHARA AND
DILIPKUMAR PAL

15.1 Introduction 339

15.2 Drug delivery using various biological macromolecules 340

15.2.1 Drug delivery using carbohydrates 341

15.2.2 Drug delivery using proteins and peptides 349

15.2.3 Drug delivery using nucleic acids 355

- 15.2.4 Drug delivery using lipids 359
- 15.3 Conclusion 367
- References 367

16. Biological macromolecules in tissue engineering

PANDURANG APPANA DALAVI,
SESHA SUBRAMANIAN MURUGAN,
SUKUMARAN ANIL AND JAYACHANDRAN VENKATESAN

- 16.1 Introduction 381
- 16.2 Bone tissue engineering 381
- 16.3 Biological macromolecules in bone tissue engineering 382
 - 16.3.1 Alginate 382
 - 16.3.2 Chitosan 383
 - 16.3.3 Carrageenan 384
 - 16.3.4 Fucoidan 385
 - 16.3.5 Ulvan 385
 - 16.3.6 Gelatin 386
- 16.4 Conclusion 387
- Acknowledgment 387
- References 387

17. Biological macromolecules for drug delivery in tissue engineering

MARCEL POPA AND LEONARD IONUT ATANASE

- 17.1 Introduction 393
- 17.2 Drug-loaded electrospun fibers used in tissue engineering applications and drug delivery 394
 - 17.2.1 Drug-loaded polysaccharides-based electrospun fibers 395
 - 17.2.2 Drug-loaded protein-based electrospun fibers 401
- 17.3 Drug-loaded injectable hydrogels used in tissue engineering applications and drug delivery 403
- 17.4 Conclusions 411
- References 411

18. Biological macromolecules for growth factor delivery

M.D. FIGUEROA-PIZANO

- 18.1 Introduction 419
- 18.2 Delivery systems for growth factors 421
- 18.3 Materials for delivery systems of growth factors 423

18.4 Biological macromolecules for delivery systems of growth factors 424

- 18.4.1 Protein-based materials for growth factor delivery 425
- 18.4.2 Polysaccharide-based materials for growth factor delivery 427
- 18.4.3 Polysaccharide combinations for growth factor delivery 429
- 18.4.4 Composites materials for growth factor delivery 430
- 18.4.5 Protein-based composite for growth factor delivery 430
- 18.4.6 Protein-polysaccharide composites for growth factor delivery 432
- 18.4.7 Polysaccharide-polysaccharide composites for growth factor delivery 433

References 433

19. Biological macromolecules for growth factor delivery in bone regeneration

ARISTEIDIS PAPAGIANNOPOULOS AND ELENI VLASSI

- 19.1 Introduction 439
- 19.2 Bone regeneration 439
- 19.3 Growth factors in tissue and bone regeneration 441
- 19.4 Biomacromolecules as carriers of growth factors 443
- 19.5 Hydrogels and sponges 445
- 19.6 Scaffolds and fibers 446
- 19.7 Nanoparticles and nanoassemblies 448
- 19.8 Concluding remarks 449
- References 449

20. Biological macromolecules for nutrients delivery

LONG CHEN, ZHONGYU YANG, DAVID JULIAN MCCLEMENTS, ZHENG YU JIN AND MING MIAO

- 20.1 Introduction 455
- 20.2 Nutrients 455
 - 20.2.1 Water-soluble nutrients 456
 - 20.2.2 Oil-soluble nutrients 458
- 20.3 Biological macromolecules used for nutrients delivery 458
 - 20.3.1 Polysaccharides 459
 - 20.3.2 Proteins 461
 - 20.3.3 Glycoproteins and proteoglycans 461

- 20.3.4 Others (lignin as example) 462
- 20.4 Molecular interactions that maintain the stability of biopolymer-based delivery systems 462
 - 20.4.1 Electrostatic interactions 463
 - 20.4.2 Hydrogen bonding 463
 - 20.4.3 Hydrophobic interactions 463
 - 20.4.4 Covalent interactions 464
- 20.5 Retention and release mechanisms 464
- 20.6 Nutrient delivery systems based on biological macromolecules 465
 - 20.6.1 Composition and structure 465
 - 20.6.2 Fabrication 466
 - 20.6.3 Properties 469
 - 20.6.4 Applications 469
- 20.7 Future trends 471
 - 20.7.1 Co-encapsulation of multiple nutrients 471
 - 20.7.2 Targeted and controlled release of bioactive molecules 471
 - 20.7.3 In vivo testing 472
- References 472

21. Biological macromolecules for nucleic acid delivery

AHMED S. ABO DENA AND IBRAHIM M. EL-SHERBINY

- 21.1 Introduction 479
- 21.2 Nucleic acids structure and functions 480
- 21.3 Biological macromolecules for nucleic acid delivery 482
 - 21.3.1 Lipid-based drug delivery systems 482
 - 21.3.2 Protein-based drug delivery systems 484
 - 21.3.3 Carbohydrate-based drug delivery systems 486
- 21.4 Conclusions 488
- References 489

22. Biological macromolecules in cell encapsulation

MILAN MILIVOJEVIC, IVANA PAJIC-LIJAKOVIC AND BRANKO BUGARSKI

- 22.1 Introduction 491
- 22.2 Biopolymers used for cell encapsulation in TE 496
 - 22.2.1 Agarose 496
 - 22.2.2 Alginate 497
 - 22.2.3 Chitin and chitosan 499

- 22.2.4 Collagen 500
- 22.2.5 Gelatin 503
- 22.2.6 Fibrin 504
- 22.2.7 Glycosaminoglycans 505
- 22.2.8 Silk (fibroin and spidroin) 506
- 22.2.9 Other natural polymers in TE 508
- 22.3 Advantages, drawbacks, applications, forms and manufacturing methods 511
- 22.4 Conclusions 526
- Acknowledgment 527
- References 527

23. Biological macromolecules for enzyme immobilization

HAMZA RAFFEEQ, SARMAD AHMAD QAMAR, HIRA MUNIR, MUHAMMAD BILAL AND HAFIZ M.N. IQBAL

- 23.1 Introduction 529
- 23.2 Biological macromolecules for enzyme immobilization 532
 - 23.2.1 Chitin and chitosan 532
 - 23.2.2 Agarose 533
 - 23.2.3 Alginate 534
 - 23.2.4 Cellulose and its derivatives 535
 - 23.2.5 Gelatin for enzyme immobilization 536
 - 23.2.6 Dextran for enzyme immobilization 537
 - 23.2.7 Pectin for enzyme immobilization 539
 - 23.2.8 Xanthan for enzyme immobilization 540
- 23.3 Conclusions and future outlook 541
- Acknowledgment 541
- Conflicts of interest 541
- References 542
- Further reading 546

24. Carbohydrates mimetics: enzyme inhibitors and target molecules in several diseases

VERÓNICA E. MANZANO, CUSTODIANA A. COLMENAREZ LOBO AND EVANGELINA REPETTO

- 24.1 Introduction 547
 - 24.1.1 Biomass and biobased materials 547
 - 24.1.2 Carbohydrates 548
 - 24.1.3 Biological and medicinal interest of carbohydrates 550
 - 24.1.4 Glycosidases 551
- 24.2 Glycomimetics 554
 - 24.2.1 Iminosugars 554

24.2.2 Carbasugars	561
24.2.3 Thiosugars	564
24.3 Hybrid carbohydrates	566
24.4 Macromolecules	567
24.4.1 Multivalents	567
24.4.2 Polysaccharides	569
24.5 Conclusions	570
References	570

IV

Others

25. Current challenging issues of biological macromolecules in biomedicine

Y. DE ANDA-FLORES, E. CARVAJAL-MILLAN,
A.C. CAMPA-MADA, K.G. MARTÍNEZ-ROBINSON,
J. LIZARDI-MENDOZA, A. RASCÓN-CHU,
A.L. MARTÍNEZ-LÓPEZ AND J. TANORI-CORDOVA

25.1 Introduction	581
25.2 Biological macromolecules	582
25.3 Macromolecules in biomedical applications	583
25.4 Macromolecules in targeted drug delivery	584
25.5 Biomaterials as targeted drug delivery	585
25.5.1 Hydrogels for drug delivery	585

25.5.2 Gene delivery	592
25.6 Macromolecules on tissue engineering	593
25.6.1 Wound management	597
25.6.2 Development of skin substitutes	597
25.7 Conclusion	600
References	600

26. Future perspectives of biological macromolecules in biomedicine

ANA R. NEVES, RÚBEN FARIA, TÂNIA ALBUQUERQUE,
TELMA QUINTELA, ÂNGELA SOUSA AND DIANA COSTA

26.1 Bio-nanotechnology	607
26.1.1 Delivery systems	608
26.2 Mitochondrial gene therapy	610
26.2.1 Mitochondrion	611
26.2.2 Mitochondrial mutations	611
26.2.3 Targeting Mitochondria	612
26.3 Crosstalk between chronobiology and cancer	616
26.3.1 Circadian clock and cancer development	617
26.3.2 Chronobiology and cancer treatment	619
26.4 Concluding remarks	624
References	625

Index 633

Biological macromolecules from algae and their antimicrobial applications

Natanamurugaraj Govindan^{1,2}, *Gaanty Pragas Maniam*^{1,2},
Mohd Hasbi Ab. Rahim^{1,2}, *Ahmad Ziad Sulaiman*³ and *Azilah Ajit*⁴

¹Algae Culture Collection Center & Laboratory, Faculty of Industrial Sciences and Technology, Universiti Malaysia Pahang, Kuantan, Malaysia ²Centre for Research in Advanced Tropical Bioscience, Universiti Malaysia Pahang, Kuantan, Malaysia ³Faculty of Bio-Engineering & Technology, University Malaysia Kelantan Kampus Jeli, Kelantan, Malaysia ⁴Faculty of Chemical & Natural Resources Engineering, Universiti Malaysia Pahang, Kuantan, Malaysia

8.1 Introduction

Algae are the dominated diverse group of the unicellular and multicellular organisms in the eukaryotic phylum. They have close resemblance with photosynthetic plants in the form of metabolic pathways, but the actual root systems are not similar (Delwiche, Andersen, Bhattacharya, Mishler, & McCourt, 2004). Microalgae can be cultured using ordinary or simulated lights using freshwater, marine water blackish water, and waste effluent that feed the species and at the same time removing nutrients and organic pollutants from the effluent (Garcia-Moscoso, Teymouri, & Kumar, 2015). Peptides (BP) are specific protein fragments that are involved in a wide range of therapeutic activities as antihypertensive, antioxidant, antitumoral, antiproliferative, hypocholesterolemic, and anti-inflammatory (Sánchez & Vázquez, 2017). Besides, they are also involved in triggering mechanisms to

stimulate healthy cell growth (Hartmann & Meisel, 2007). Microalgae antimicrobial peptides (AMPs) have several advantages including gene expression similar to higher plants and efficiently can be grown for numerous applications.

8.2 Bioactive macromolecules

8.2.1 Terpenoids



Culturing of algae has been exponentially increasing along course of decades due to the exploration of unique bioactive compounds available in various forms of algae species. Terpenoids are the class of bioactive components present in several marine algae species. Based on the number of isoprene units, terpenoids are further classified as monoterpenoids, sesquiterpenoids, diterpenoids, sesterterpenoids, triterpenoids, tetraterpenoids



Chapter 8 - Biological macromolecules from algae and their antimicrobial applications

Natanamurugaraj Govindan^{1,2}, Gaanty Pragas Maniam^{1,2}, Mohd Hasbi Ab. Rahim^{1,2}, Ahmad Ziad Sulaiman³, Azilah Ajit⁴

Show more 

+ Add to Mendeley  Share  Cite

<https://doi.org/10.1016/B978-0-323-85759-8.00008-7>

[Get rights and content](#)

Abstract

Algae are the dominated diverse group of the unicellular and multicellular organisms in the eukaryotic phylum. They have close resemblance with photosynthetic plants in the form of metabolic pathways, but the actual root systems are not similar. Microalgae can be cultivated using natural or artificial light systems using freshwater, marine water blackish water and even wastewater providing additional benefit by removing nutrients and organic pollutants from wastewater. Peptides (BP) are specific protein fragments that are involved in a wide range of therapeutic activities as antihypertensive, antioxidant, antitumoral, antiproliferative, hypocholesterolemic, and antiinflammatory. Besides, their also involved triggering mechanisms as well as nutritive function that providing the amino acid units as building blocks for new proteins to cells. Microalgae antimicrobial peptides (AMPs) have several advantages including gene expression similar to higher plants and cost effective phototrophic cultivation with simple and inexpensive medium and a safe food additive, so oral delivery of AMPs containing algae is possible.

Keywords

Algae; macromolecules; antimicrobial compounds; seaweed; metabolic pathways

Index

Note: Page numbers followed by “f” and “t” refer to figures and tables, respectively.

- A**
Aceclofenac, 349
Acetaminophen, 342
Acetohexamide, 229–230
Acetylcholinesterase (AChE), 566
Acetylglucosamine, 72–73
Acotinum coreanum, 254–255
Acylated homoserine lactones (AHLs), 32–33
Adalimumab, 60, 274–275
Adenine (A), 61, 481–482
Adenosine diphosphate (ADP), 15
Adenosine triphosphate (ATP), 15
Adipose-derived stem cells (ADSCs), 383
Ag nanoparticles (AgNP), 187
Agar, 9
 agar-based injectable hydrogels, 410–411
Agaricus bisporus, 36–37
Agarose, 496–497, 533–534
Agarwood, 266
Age-related macular degeneration (AMD), 106
Agrobacterium tumefaciens, 32–33
Albuminoids, 13
Albumins, 12
 albumin-based nanostructures, 484
Algae, 203
 bioactive macromolecules, 203–213
 alkaloids, 208
 peptides, 209–210
 phenolics, 207–208
 polyketide, 210
 polysaccharides, 208–209
 steroids, 206–207
 terpenoids, 203–206
 polyunsaturated fatty acids, 210–213
Algal-derived proteins, 151–152
Alginate(s), 3–4, 7–8, 8f, 128, 173, 183–184, 382–383, 408, 460, 497–499, 534–535, 585–586
 alginate-based hydrogels, 407–408
 alginate-based nanocomposite, 187
Alginic acid, 460
Alicyclobacillus acidoterrestris, 32–33
Alkaline phosphatase (ALP), 383–384
Alkaloids, 99–102, 208
 caffeine, 99–100
 capsaicin, 101
 chemical structure of, 101f
 theobromine, 101–102
Alkyl spacer, 313
All-trans retinoic acid (atRA), 396
Allergen immunotherapy, 591–592
Allograft techniques, 381
Allophycocyanin, 151
Alpha-linolenic acid (ALA), 210–211
 α -amylase, 230
 α -bisobolol (BIS), 401
 α -cyclodextrin (α CD), 587
 α -galactosidase, 569
 α -glucosidase inhibitors, 230, 560
 α -linolenic acid, 120
 α -mannosidase, 569
 α -pentagalloylglucose (α -PGG), 566–567
Alzheimer’s disease (AD), 3–4, 219, 612
Amantadine, 317
Amino acids, 24
 deficiency, 297–298
5-amino-5-deoxy-D-glucose, 554–555
Aminoglycosides, 307–308
Aminolipids, 483
Amoxicillin, 395
AMP-activated protein kinase (AMPK), 256
Amphenicols, 307–308
Amyloid-beta and tau protein, 219–220
Amylopectin, 289–290, 460–461, 508–509
Amylose, 289–290, 460–461, 508–509
Andrographis paniculata, 146
Angelica sinensis, 141
Animal derived carbohydrates with nutraceutical activity, 126
Animal-derived polysaccharides, 146–147
Animal-derived proteins, 150–151
Annona squamosa, 569–570
Antheraea pernyi, 506–507
Anthocyanins, 103
Anti-IL-23 antibody, 274–275
Antibacterial activity, synthetic macromolecules with, 313–317, 314f
Antibiotic(s), 99, 307–308
 drugs, 165
 resistant tuberculosis, 306
Anticancer agents
 biological macromolecules for cancer therapy, 244–269
 carbohydrates, 244–258
 lipids, 262–269
 natural compounds or biological macromolecules, 245f
 proteins and nucleic acid, 258–262
Antidiabetic agents
 advantages, limitations, and future perspectives, 238
 biological macromolecules, 232–238
 types, 230–232
Antifungal activity, synthetic macromolecules with, 318–319
Antifungal polymers, 306
Antigen presenting cells (APCs), 275

- Antimicrobial activity, 306
 antibacterial activity, synthetic
 macromolecules with, 313–317
 antifungal activity, synthetic
 macromolecules with, 318–319
 antiparasitic activity, synthetic
 macromolecules with, 319–320
 antiviral activity, synthetic
 macromolecules with, 317–318
 classification of antimicrobial
 polymers, 308–309
 factors affecting antimicrobial
 activity, 311–313
 alkyl spacer, 313
 charge density, 312–313
 counter ion effect, 312
 hydrophilic/hydrophobic
 balance, 311–312
 molecular weight, 312
 polymeric architecture, 313
 history of antimicrobial agents and
 antimicrobial polymers,
 307–308
 preparation routes for antimicrobial
 polymers, 309–311
 synthetic macromolecules with,
 306–320
- Antimicrobial agents, 306–308
 antimicrobial activity of biological
 macromolecules, 172–180
 fatty acids, 177–180
 polysaccharides, 172–174
 proteins, 175–177
 antimicrobial activity of
 macromolecule composites,
 180–185
 chitosan-alginate, 180–181
 chitosan-cellulose, 184
 collagen-alginate, 183–184
 gelatin-chitosan, 181–182
 keratin-chitosan, 182–183
 lactoferrin-oleic acid, 185
 applications, 190–193
 drug delivery, 191–192
 food packaging, 190–191
 wound dressing, 192–193
 classification of biological
 macromolecule, 167–172
 carbohydrate, 167–169
 lipid, 170–171
 protein, 169
 nanotechnology based antimicrobial
 macromolecule, 185–190
- Antimicrobial peptides (AMPs),
 183–184, 203, 307–308
 Antimicrobial polymers, 307–308
 classification of, 308–309
 preparation routes for, 309–311
 Antimicrobial surfaces, 308
 Antimicrobials, 471
 Antioxidants, 140–141, 320
 activity
 methods evaluation of
 antioxidant activity, 325*t*
 synthetic macromolecules with,
 320–324
 food-based applications, 156–158
 future trends, 159
 limitations of biological
 macromolecules, 158–159
 macromolecules as, 152–156
 polymers, 306
 types and sources of biological
 macromolecules, 141–152
 Antioxidative macromolecules, 152
 nonextractable polyphenols, 152
 Antiparasitic activity, synthetic
 macromolecules with, 319–320
 Antisense oligonucleotides, 62,
 584–585
 Antiviral activity, synthetic
 macromolecules with, 317–318
 Antiviral polymers, 306
Antrodia cinnamomea, 257
 Apolar lipids, 120
 Aptamer, 63
 Arabinose (Ara), 254
 Arabinoxylans (AX), 585–586
 Arachidonic acid (AA), 180, 278–279
 Arctigenin (Arc), 253
Arctium lappa, 253
Armoracia rusticana, 535
 Asamycines, 307–308
Ascophyllum nodosum, 232
 Ascorbic acid (C₆H₆O₆), 456
 Aspergillosis, 318
Aspergillus
A. aculeatus, 535
A. flavus, 41
A. fumigatus, 318
A. niger, 172
Astragalus
A. membranaceus, 254
A. membranaceus, 141–146
 Astragalus polysaccharide (APS),
 254
- Atom transfer radical polymerization
 (ATRP), 309–310
Aureobasidium pullulans, 510–511
Auricularia polytricha, 292
 Autografts, 599
 techniques, 381
Avena sativa, 232
 Avian influenza A, 306
Avrainvillea, 204
- ## B
- B-glucans, 276
Bacillus
B. cereus, 31
B. subtilis, 42, 204–206
B. thuringiensis, 32–33
Bacillus striatum polysaccharide (BSP),
 128–129
 Bacterial cellulose (BC), 173
 Bacterial polysaccharides, 149
 Bacteroides, 590
 Barium titanium (BaTiO₃), 596–597
 Base pairs (BP), 481
 Beads-free fibers, 401–402
 Beetle (*Massonia pustulata*), 261–262
 1,4-benzoquinone moiety, 205
 Bergamot essential oil (BEO), 265
 Bergapten-free BEO (BEO-BF), 265
 β-carotene, 105–106, 458
 β-galactosidase, 569
 β-glucan, 56
 β-glucocerebrosidase (GCase), 557
 β-lactoglobulin, 461
 β-(1,4)-linked D-glucosamine,
 72–73
 β-mannosidase, 569
 β-N-acetylhexosaminidase OfHex1,
 565–566
 ureido thioglycosides inhibitors of,
 566*f*
 β-tricalciumphosphate (β-TCP), 395
 Bicyclic iminosugars, 559–560, 560*f*
 Bifidobacteria, 590
 Bio-catalysis, 529
 Bio-nanotechnology, 607–610
 delivery systems, 608–610
 Bioactive compounds, 305
 Bioactive lipids, 120
 in cancer stem cells, 123–124
 Bioactive macromolecules, 305
 Bioactive materials, 315
 Bioactive molecules, 471–472
 Bioactive peptides, 109–110, 308

- Bioactive polysaccharide, chitosan as, 36–42
- Bioactive proteins, 14
enzymes as, 24–36
- Biobased materials, 547–548
- Biocatalysts, 529
- Biocidal polymers, 308
- Bicide releasing polymers, 308
- Biocompatibility, 492
- Biodegradable chitosan, 349
- Biodegradable polymers, 393
- Biological interest of carbohydrates, 550–551
- Biological macromolecules, 3, 23, 53, 69, 70*f*, 141, 166, 339–340, 381, 479–480. *See also* Synthetic macromolecules
- as antidiabetic agents, 232–238
- carbohydrates, 232–233
- lipids, 233–234
- nucleic acids, 237–238
- proteins, 235–237
- bio-nanotechnology, 607–610
- in BTE, 382–387
- for cancer therapy, 244–269
- carbohydrates, 4–9
- crossstalk between chronobiology and cancer, 616–624
- chronobiology and cancer treatment, 619–624
- circadian clock and cancer development, 617–619
- drug delivery using, 340–367
- for enzyme immobilization, 532–541
- lipids, 9–11
- mitochondrial gene therapy, 610–616
- nucleic acids, 14–17
- for nucleic acids delivery, 482–488
- for nutrients delivery, 458–462
- nutrients delivery systems based on, 465–471
- proteins, 11–14
- sources and bioactivities of macromolecules, 142*t*
- types and sources of, 141–152
- antioxidative macromolecules, 152
- polysaccharides, 141–149
- proteins, 149–152
- Biomacromolecules, 191–192, 581
- Biomass, 547–548
- Biomaterials
- of biomedical, 581
- as targeted drug delivery, 585–593
- gene delivery, 592–593
- hydrogels for drug delivery, 585–592
- Biomedicine, 64
- biological macromolecules in, 53–54, 582–583
- carbohydrates, 54–56
- chemical properties and functions of, 583*t*
- lipids, 60–61
- nucleic acids and
- oligonucleotides, 61–63
- peptides, 56–58
- proteins, 58–60
- synthesis of macromolecules, 63–64
- biomaterials as targeted drug delivery, 585–593
- macromolecules in
- biomedical applications, 583–584
- targeted drug delivery, 584–585
- macromolecules on tissue engineering, 593–599
- nucleic acids and nutraceutical properties used in, 112–119
- Biomolecules, 274–275
- biomolecules-based therapeutics, 53
- Biopassive materials, 313–315
- Biopolymers, 403, 440–441, 492–493, 495
- biopolymer-based delivery systems, 462–464
- covalent interactions, 464
- electrostatic interactions, 463
- hydrogen bonding, 463
- hydrophobic interactions, 463–464
- other natural polymers in TE, 508–511
- used for cell encapsulation in TE, 496–511
- agarose, 496–497
- alginate, 497–499
- chitin and chitosan, 499–500
- collagen, 500–502
- fibrin, 504–505
- gelatin, 503–504
- glycosaminoglycans, 505–506
- silk, 506–508
- Biosafety, 492
- Biosensing, 113–114
- Biotransformation of food, 289
- Bixalomer, 327–328
- Bletilla striata*, 292–294
- Blowfly (*Chrysomya megacephala*), 146
- Bombyx mori*, 506–507
- Bone morphogenic proteins (BMPs), 445
- Bone regeneration, 439–441
- growth factors in, 441–443
- scaffolds and fibers, 446–447
- Bone remodeling, 596
- Bone tissue engineering (BTE), 381–382
- biological macromolecules in, 382–387
- alginate, 382–383
- carrageenan, 384–385
- chitosan, 383–384
- fucoidan, 385
- gelatin, 386–387
- ulvan, 385–386
- strategy, 596–597
- Bordetella bronchiseptica*, 149
- Bovine lactoferrin, 176–177
- Bovine serum albumin (BSA), 399, 448
- nanoparticles, 352–353
- Brain cancer, lipids in, 265–266
- Branched PEI (bPEI), 609–610
- Breast cancer
- carbohydrates in, 252–255
- lipids in, 264–265
- proteins and nucleic acid in, 259–261
- Brome mosaic virus (BMV), 117
- Brown alga (*Sargassum henslowianum*), 148
- Buccal patches, 349
- Butanetetracarboxylic acid, 397
- Butylated hydroxyanisole (BHA), 321
- Butylated hydroxytoluene (BHT), 321
- Butyrylcholinesterase (BuChE), 566
- C**
- C-type lectins, 222
- Caffeine, 99–100
- Calcium phosphate cement (CPC), 433
- Calcium Resonium, 327
- Callophyllis conceptionensis*, 156
- Campylobacter jejuni*, 176–177
- Cancer Genome Atlas, 618
- Cancer(s), 3–4, 243, 306
- bioactive lipids in, 123

- Cancer(s) (*Continued*)
 cancer stem cells, 123–124
 cancer chronodrug/gene delivery, 620–624
 chronobiology and, 616–624
 circadian clock and cancer development, 617–619
 list of cancer chronotherapy studies in cancer patients, 621*t*
 of GS, 289
Candida albicans, 42, 318
 Candidiasis, 318
 Cantharidin, 261–262
 Capsaicin, 101
Capsicum
C. annuum, 101
C. baccatum, 101
C. chinense, 101
C. frutescens, 101
C. pubescens, 101
Capsosiphon fulvescens (CF), 251–252
 Carbasugars, 561–564
 analogs to N-Acetyl glucosamine, 564*f*
 natural, 562*f*
 Carbazole-loaded gliadin nanoparticles, 354
 Carbohydrate macromolecules.
See also Synthetic macromolecules
 biological macromolecules, 70*f*
 cellulose, 69–71
 chitin and chitosan, 72–73
 hemicelluloses, 71–72
 lignin, 72
 modification of carbohydrate
 biological macromolecules, 73–86
 chemical modification of
 cellulose, 75*t*
 chemical modification of chitin/
 chitosan, 80*t*
 chemical modification of lignin, 76*t*
 classification of modification, 73*f*
 enzymatic modification of
 cellulose, 76*t*
 enzymatic modification of chitin/
 chitosan, 84*t*
 enzymatic modification of lignin, 77*t*
 modification techniques for
 hemicellulose, 74*f*
 physical modification of cellulose, 74*t*
 physical treatments for chitin/
 chitosan, 80*t*
 principle groups of carbohydrates
 macromolecule, 70*f*
 Carbohydrate-active enzymes
 (CAZymes), 551
 Carbohydrate(s), 3–9, 23, 53–56, 124, 222–223, 230, 305, 548–550, 582–583
 as antidiabetic agents, 232–233
 as antimicrobial agents, 167–169
 disaccharide, 167–168
 monosaccharide, 167
 oligosaccharide, 168
 polysaccharide, 168–169
 biological and medicinal interest of
 carbohydrates, 550–551
 biomedical applications of, 550*f*
 for cancer therapy, 244–258
 breast cancer, 252–255
 cervical cancer, 244–250
 colon cancer, 250–252
 lung cancer, 255–257
 others, 258
 pancreatic cancer, 257–258
 carbohydrate-based drug delivery
 systems, 486–488
 carbohydrate-based macromolecular
 systems, 549
 drug delivery using, 341–349, 350*t*
 esterases, 551
 glycomimetics, 554–566
 glycosidases, 551–553
 classes of enzymes, 552*f*
 hybrid, 566–567
 molecular diversity in biological
 applications, 549*f*
 monosaccharides, 5
 as nutraceuticals, 124–129
 alginate, 128
 animal derived carbohydrates
 with nutraceutical activity,
 126
 BSP, 128–129
 carbohydrates from plants with
 nutraceutical activity, 125
 carbohydrates with nutraceutical
 activity from microorganisms,
 128
 cellulose and hemicellulose,
 125–126
 chitosan and chitin, 127–128
 dextran, 128
 heparin, 126–127
 hyaluronic acid, 127
 immunostimulatory effect of
 carbohydrates, 125
 polysaccharides role in
 extracellular membrane,
 124–125
 oligosaccharides, 5
 polysaccharides, 5–9
 role in gastrointestinal system,
 289–295
 role on nervous system, 223
 in retino-tectal system, 223
 therapeutics based on
 carbohydrates, 55–56
 Carbon, 4
 Carboxylated cellulose nanocrystals
 (CCNCs), 397–398
 Carboxylic acids, 177
 Carboxymethyl-hexanoyl derivative,
 232–233
 Carboxymethylcellulose (CMC), 42,
 397, 429
 Cardiovascular diseases, 419–421
 Carrageenan, 3–4, 384–385, 460, 509
 for enzyme immobilization,
 537–539
 Casein, 461
 Casein-coated diltiazem HCl, 351
Cassia obtusifolia L., 146
Cassia tora L., 146
 Castleman's disease, 274–275
 Catalase, 140–141
 Catechol-modified methacryloyl
 chitosan, 407
 Cationic human-serum albumin
 (CHSA), 485
 Cationic lipids, 609
 Cationic polymerization, 309–310
 CCK-8 assay kit, 256
Cedrelopsis grevei, 265
 Cell
 biology studies, 401
 cell-penetrating peptides, 610
 cell-signaling, 441
 cycle proteins in CNS injury, 220,
 221*f*
 proliferation, 441–442
 replication, 16
 targeting strategy, 608–609
 Cell encapsulation

- advantages, drawbacks,
 applications, forms and
 manufacturing methods,
 511–525
 characteristics and applications of
 biopolymers used TE, 512*t*
 main forms and manufacturing
 methods for biopolymers used
 TE, 524*t*
 biological macromolecules used in,
 493*t*
 biopolymers used for cell
 encapsulation in TE, 496–511
 methods, 491–492
 Cell-wall targeting (CWT), 28–30
 Cellular damages, 27
 Cellular processes, 441
 Cellulose, 6, 7*f*, 69–71, 125–126, 166,
 168–169, 169*f*, 173, 289–290,
 508
 based nanocomposite, 187–189
 chemical modification of, 75*t*
 and derivatives for enzyme
 immobilization, 535–536
 enzymatic modification of, 76*t*
 molecular structure of cellulose
 molecule-numbering system,
 71*f*
 physical modification of, 74*t*
 Cellulose acetate (CA), 397–398
 Cellulose nanocrystals (CNC), 6, 173
 Central composite rotational design
 (CCRD), 535
 Central fatty hypothesis, 222
 Central nervous system (CNS), 3–4,
 219
 carbohydrates, 222–223
 role on nervous system, 223
 in case of neurodegenerative
 diseases, 225
 cell cycle proteins, 220
 central fatty hypothesis, 222
 cPLA2 role in cerebral ischemia,
 225
 glycans, 223–224
 role in neural development, 224
 homer/vesl proteins, 220–222
 lipids, 224–225
 peroxidation, 225–226
 proteins, 219–220
 in sensory organs, 223
 Cephadrine, 409
 Cephalins, 10
 Cerebral ischemia, cPLA2 role in, 225
 Cerium (Ce), 384–385
 Cervical cancer, carbohydrates in,
 244–250
 Chaga mushroom (*Inonotus obliquus*),
 256
 Charge density, 312–313
 Chelating agent soluble solids (CHSS),
 249
 Chemically modified polymers, 309
 Chemotherapy, 608–609
Chenopodium quinoa, 236–237
 Chitin, 72–73, 127–128, 499–500
 chemical modification of, 80*t*
 enzymatic modification of, 84*t*
 for enzyme immobilization,
 532–533
 physical treatments for, 80*t*
 Chitosan (CS), 3–4, 8–9, 72–73,
 127–128, 166, 172, 191,
 232–233, 252–253, 276–277,
 383–384, 395, 486–487,
 499–500, 585–586, 593, 596
 based nanocomposite, 185–187
 as bioactive polysaccharide, 36–42
 bioactivity of chitosan with
 modified functional group,
 41–42
 relationship of chitosan
 physicochemical property and
 bioactivity, 37–40
 chemical modification of, 80*t*
 chitosan-alginate, 180–181, 429–430
 chitosan-cellulose, 184
 chitosan-clay-based biocomposite,
 533
 enzymatic modification of, 84*t*
 for enzyme immobilization,
 532–533
 physical treatments for, 80*t*
 Chitosan oligosaccharide (CSO-OA),
 179, 292
Chlorella pyrenoidosa, 252
Chlorococcum sp., 252
 Chlorpropamide, 229–230
 Cholesterol, 11, 170–171
 conjugated 5-fluorouracil, 361
 Cholestyramine, 326
Chondrococcus hornemanni, 205
 Chondroitin, 166, 173–174
 Chondroitin sulfate (CS), 173–174,
 429, 505
 Chromoproteins, 13
 Chronobiology and cancer treatment,
 616–624
 Chronodrug delivery systems
 (ChrDD), 616–624
Chrysomya megacephala. See Blowfly
 (*Chrysomya megacephala*)
 Cigarette smoke, 139
 Ciprofloxacin (CP), 173, 264, 352
 HCl, 398
 Circadian clock, 617
 and cancer development, 617–619
 dysregulation, 619
Citrullus lanatus, 236–237
 Clarithromycin, 354
 Click chemistry, 309–310
 Clock-controlled genes (CCGs), 617
 Clove buds (*Syzygium aromaticum*),
 268–269
 Coacervation-gelation methods,
 466–467
 Coagulated proteins, 14
 Coaxial emulsion electrospinning, 400
Cocculas hirsutus, 347–349
Codium iyengarii, 206
 Cohesive system, 64
 Colesevelam, 326–327
 Colestimide, 326–327
 Colestipol, 326
 Collagen, 166, 175, 402, 426, 432,
 500–502, 501*f*
 based nanocomposite, 190
 collagen-alginate, 183–184
 Collagen-binding VEGF (CB-VEGF),
 426
 Colon cancer, 250–252
 carbohydrates in, 250–252
 lipids in, 263–264
 proteins and nucleic acid in, 259
 Colony forming unit (CFU), 183–184
 Colorectal cancer (CRC), 590
 proteins and nucleic acid in,
 259–261
Combretum caffreum, 244
 Communicable diseases (CDs), 98
 Composites materials for GFs
 delivery, 430
 Compound lipids, 10
 Concentrated alkali soluble solids
 (CASS), 249
 Conjugate lipids, 10
 Conjugated proteins, 13
 Constipation, 289
 Convulsive disorders, 3–4

- Cordyceps sinensis*, 256
 Corn silk polysaccharide (CSP), 244
 Coronary diseases, 419–421
 Coronavirus (CoVs), 111–112
 Coronavirus disease (COVID-19), 123
 bioactive lipids in, 123–124
Corynebacterium diphtheriae, 206
 Counter ion effect, 312
 Covalent bonding, interaction with, 531–532
 Covalent interactions, 464
 cPLA2 role in cerebral ischemia, 225
 CRISPR, 117–119
 Crohn's disease, 281–282
Croton flavens L., 263
Cryptococcus neoformans, 318
 CsNP. *See* Nanoparticles from chitosan (CsNP)
Cucurbita
 C. moschata, 232
 C. pepo, 236–237
Curcuma longa. *See* Turmeric (*Curcuma longa*)
 Curcumin, 98, 102–103, 354–355, 458, 592
 Cutaneous Leishmaniasis, 319
 Cyanobacteria, 259–260
 Cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS), 276–277
 Cyclin-dependent kinase (CDK), 219, 619–620
 Cyclodextrin, 445–446
 Cyclopentano perhydro phenantherene, 11, 11f
 Cyclophosphamide, 354
 Cysteine, 396
 Cystic fibrosis, 593
 Cytidine diphosphate (CDP), 15
 Cytidine triphosphate (CTP), 15
 Cytochrome c, 256
 Cytosine (C), 61, 481–482
 Cytotoxicity, 583–584
 test, 250–251
- D**
 D-galactose, 566
 D-ribose, 566
 D-xylose, 566
 DC-specific intracellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), 282
 Deacetylation degree (DD), 276–277
 Dectin-1, 276
 Degummed silk fibroin, 507
 Delivery systems, 469
 bio-nanotechnology in, 608–610
 nonviral vectors, 608–610
 for GFs, 421–423
 biological macromolecules for, 424–433
 composites materials for, 430
 materials for, 423–424
 polysaccharide combinations for, 429–430
 polysaccharide-based materials for, 427–429
 polysaccharide-polysaccharide composites for, 433
 protein-based composite for, 430–432
 protein-based materials for, 425–427
 protein-polysaccharide composites for, 432–433
 Denaturation-gelation method, 467
 Dendrimers, 318, 592, 609
 Dendritic cells (DCs), 280
 Deoxycytidine (dCyd), 264
 Deoxygalactonojirimycin (DGJ), 556
 Deoxymannojirimycin (DMJ), 556
 1-deoxynojirimycin (1-DNJ). *See* 1,5-dideoxy-1,5-imino-D-glucitol
 Deoxynojirimycin FA-DNJ, 569
 Deoxyribonucleic acid (DNA), 3, 15–16, 61, 171–172, 230, 480, 481f, 582–583
 fragmentation, 27
 functional sequence, 116–119
 CRISPR, 117–119
 gene therapy, 117
 non-mRNA sequences, 116–117
 nanostructures, 113–116
 biosensing, 113–114
 drug delivery, 114–115
 immunomodulatory, 115–116
 nanotechnology, 358
 Deoxyribose, 61
 Derived lipids, 10–11
 Derived proteins, 13–14
 Dermatan sulfate (DS), 505
 Dermis, 597–598
Derris elliptica, 554–555
 Dexamethasone (DXM), 401–402
 Dextran (Dex), 7, 128, 399, 509–510, 585–586
 for enzyme immobilization, 537–539
 carrageenan for enzyme immobilization, 537–539
 Dextran sulfate sodium (DSS), 289–290
 DHA. *See* Docosahexaenoic acid (DHA)
 Diabetes, 229
 Diarrhea, 289
 1,5-dideoxy-1,5-imino-D-glucitol, 554–555
 2,5-dideoxy-2,5-imino-D-mannitol, 554–555
 Diethyl aminoethyl (DEAE), 536
 Diffusion mechanism, 465
 2,5-dihydroxymethyl-3, 4-dihydroxypyrrolidine (DMDP), 554–555
 Diluted alkali soluble solids (DASS), 249
 Dimethyl (DM), 319
Dioscorea species, 342
 Dipetidyl-peptidase-IV (DPP-IV), 229–230
 2,2-diphenyl-1-picrylhydrazyl (DPPH), 40, 244
 Dipotassium hydrogen orthophosphate, 406
 Disaccharides (DS), 5, 167–168, 289–290
 Dissolution mechanism, 464
 Diterpenoids, 203–204
 Docosahexaenoic acid (DHA), 11, 121–123, 210–211, 278–279
 Dopamine, 222
 Doxorubicin, 352
 doxorubicin-loaded zein nanoparticles, 353–354
 Doxycycline monohydrate (DCMH), 401–402
 Dragline silk. *See* *Nephilia clavipes*
 Drug delivery, 114–115
 antimicrobial agents on, 191–192
 using biological macromolecules, 340–367
 using carbohydrates, 341–349, 350f
 using lipids, 359–367, 366f
 using nucleic acids, 355–359
 using peptides, 349–355, 356f
 using proteins, 349–355, 356f

- drug delivery-based on lipids, 60–61
- Drug delivery systems (DDSs), 393, 479
- “Drug-free” macromolecular therapeutics, 273–274
- Drug-loaded electrospun fibers in tissue engineering, 394–403
- drug-loaded polysaccharides-based ESF, 395–400
- drug-loaded protein-based ESF, 401–403
- Drug-loaded injectable hydrogels in tissue engineering, 403–411
- Drug-loaded polysaccharides-based ESF, 395–400
- Drug-loaded protein-based ESF, 401–403
- Durvillaea antarctica*, 148
- E**
- Ebola, 306
- Echinacea purpurea*, 292–294
- Eicosapentaenoic acid (EPA), 11, 121–123, 210–211, 278–279
- Elaidic acid (EA), 263–264
- Elastin, 426, 511
- Elav-like protein 1, 235–236
- Electrospinning process, 393–394, 399
- Electrospun fibers (ESF), 394–395
- drug-loaded polysaccharides-based, 395–400
- Electrostatic interactions, 463
- Elsholtzia ciliata*, 265–266
- Emulsification-gelation methods, 467
- Emulsion electrospinning, 402
- Endo-glycosidase, 552–553
- Endogenous antioxidants, 140–141
- Endogenous digestive enzymes, 230
- Engeletin (ENG), 255–256
- Enhanced permeability and retention effect (EPR effect), 358
- Enterobacteria, 590
- Enterococcus*, 173–174
- Enteromorpha*
- E. compressa*, 156
- E. linza*, 148
- Enzyme immobilization
- biological macromolecules for, 532–541
- agarose, 533–534
- alginate, 534–535
- cellulose and derivatives, 535–536
- chitin and chitosan, 532–533
- dextran, 537–539
- gelatin, 536–537
- pectin, 539–540
- xanthan, 540–541
- characteristics of enzyme immobilization platforms, 530f
- studies reporting immobilization of different enzymes using biopolymers, 531f
- Enzyme(s), 469–470, 529
- as bioactive proteins, 24–36
- LAOs, 25–28
- lysostaphin, 28–32
- metallo- β -lactamase-like lactonase, 32–36
- carbohydrates for enzyme inhibition
- biomass and biobased materials, 547–548
- glycomimetics, 554–566
- hybrid carbohydrates, 566–567
- macromolecules, 567–570
- enzyme-assisted extraction method, 230–232
- Epidermal growth factor receptor (EGFR), 281–282
- Epidermis, 597–598
- EPL. *See* Poly(ϵ -lysine) (EPL)
- Erythropoietin (EPO), 63–64
- Escherichia*, 173–174
- E. coli*, 6, 27, 42, 149, 166, 206
- Specialized metabolites with nutraceutical activity, 107, 108f
- Essential fatty acids (EFA), 120, 298–299
- Essential oil from fresh leaves of *O. kilimandscharicum* (EOOK), 266–267
- Essential oils (EO), 262–263, 267
- Ethnomedicines, 64
- Ethosomal formulation, 362–364
- Ethyl cellulose (EC), 396
- Eubacteria, 590
- Eucheuma*
- E. cottoni*, 206, 207f
- E. serra*, 209–210
- Eupatorium adenophorum* (EA), 266
- Eurysterols A, 206
- Eurysterols B, 206
- Exo-glycosidase, 552–553
- Extracellular matrix (ECM), 124–125, 393, 419, 491
- Extracellular membrane, polysaccharides role in, 124–125
- Extracellular polysaccharides (EPSS), 252
- Extraction method, 230–232
- F**
- Fabrication, 466–469
- of hydrogel, 466–467
- of microcapsules, 467–468
- of nanoparticles, 468–469
- “Facially amphiphilic” approach, 311–312
- Fascioquinols A, 205–206
- Fascioquinols B, 205–206
- Fascioquinols C, 205–206
- Fascioquinols D, 205–206
- Fats, 10
- Fatty acid methyl ester (FAME), 177–179, 212
- Fatty acids, 177
- antimicrobial activity of, 177–180
- arachidonic acid, 180
- FAME, 177–179
- linoleic acid, 179–180
- oleic acid, 179
- role in gastrointestinal system, 298–300
- Ferrier carbocyclization, 563–564
- Fibers, 446–447
- Fibrin, 166, 176, 504–505
- Fibrinogen, 426–427
- functionalization synthesis of, 431f
- Fibroblast growth factor (FGF), 442
- Fibroion, 506–508
- Fibronectin, 511
- Ficus pandurata*, 244–249
- First generation monoclonal antibodies, 59
- First-line defense antioxidants, 140–141
- Fish gelatin (FG), 598
- Flavin adenine dinucleotide (FAD), 25–26
- Flavonoids, 243
- Flavors, 469
- 5-fluorouracil (5-FU), 263–264, 361, 403
- 5-fluorouracil-loaded zein nanoparticles, 353–354

- Food additives, 158
- Food and Drug Administration (FDA), 57–58, 274–275, 280, 458, 582–583
- Food packaging, 157–158
antimicrobial agents on, 190–191
- Food-based applications
antioxidants in, 156–158
food additives, 158
food packaging, 157–158
functional foods, 156–157
other applications, 158
- Fourier transform infrared spectroscopy (FTIR), 250–251, 622–623
- Fourth generation monoclonal antibodies, 60
- Fragmentation mechanism, 465
- Free fatty acid receptor 1 (FFA-1), 233–234
- Free radicals, 139
polymerization technique, 309–310, 322–323
- Fructose, 167, 167f, 289–290
- Fucoidan (FCD), 55–56, 257, 385, 411
- Fucosterol, 206, 206f
- Functional foods, 156–157
- Functional peptides, 109–110
- Fungal infections, 318
- Fungal polysaccharides, 149, 258
- G**
- G protein-coupled receptor (GPR), 277
- Gabapentin, 397–398
- Galactomannan, 429
- Galactose (Gal), 254, 289–290
- Galacturonic acid (GalTA), 254
- Galaxaura marginata*, 209–210
- Gallic esters, 320–321
- γ -linoleic acid, 278–279
- Ganglioseries, 223
- Gas chromatography (GC), 254–255
- Gastrointestinal systems (GS), 289
carbohydrates role in, 289–295
fatty acids role in, 298–300
nucleic acids role in, 300
proteins role in, 295–298
types of biological macromolecules, 290f
- Gastrointestinal tract (GI tract), 289, 588–589
- Gelatin (Gel), 3–4, 166, 175, 386–387, 397–398, 426, 485, 503–504, 595–596
based nanocomposite, 189–190
for enzyme immobilization, 536–537
gelatin-chitosan, 181–182
hydrogels, 446
microspheres, 448
- Gellan, 510
- Gemcitabine, 264
gemcitabine-conjugated albumin nanoparticles, 352–353
- Gene delivery, 592–593. *See also* Drug delivery
cancer chronodrug/gene delivery, 620–624
- Gene expression, 614–616
- Gene Expression Omnibus, 618
- Gene therapy, 117, 608–609
- Ginseng polysaccharides (GP), 56
- Glibenclamide, 229–230
- Globoseries, 223
- Globulins, 12
- Gloiopeltis furcate*. *See* Red alga (*Gloiopeltis furcate*)
- Glucagon-like peptide-1 (GLP-1), 237–238
receptors, 229–230
- Glucose (Glc), 167, 167f, 254, 289–290
- Glutathione (GSH), 255
- Glutathione reductase, 140–141
- Glutelins, 12
- Glycans, 223–224
role in neural development, 224
- Glycine max*, 236–237
- Glycinin peptide, 176
- Glycogen, 9, 146, 289–290
- Glycolipids, 10, 548
- Glycomimetics, 549–550, 554–566
carbasugars, 561–564
iminosugars, 554–561
thiosugars, 564–566
- Glycopeptides, 307–308
- Glycoproteins, 13, 461–462, 548
- Glycosaminoglycans (GAGs), 126, 449, 505–506
- Glycosidases (GHs), 551–553
- Glycoside conformation, 548
- Glycoside hydrolases, 551
- Glycosyl hydrolases, 551
- Glycosyltransferases (GTs), 551
- Gracilaria fisheri* OS (GFOS), 292
- Gracilaria* spp., 496–497
G. chilensis, 156
G. lemaneiformis, 148
- Graft polymerization, 323
- Grafting techniques, 381
- Granulation tissue, 440
- Graphene oxide (GO), 395
- Green alga (*Ulva fasciata*), 148
- Green fluorescent protein (GFP), 612–614
- Green tea, 258
- Growth factors (GFs), 419
biological macromolecules for delivery systems of, 424–433
composites materials for, 430
polysaccharide combinations for, 429–430
polysaccharide-based materials for, 427–429
polysaccharide-polysaccharide composites for, 433
protein-based composite for, 430–432
protein-based materials for, 425–427
protein-polysaccharide composites for, 432–433
biomacromolecules as carriers of, 443–445
classification of families of, 420f
delivery systems for, 421–423
materials for delivery systems of, 423–424
in tissue and bone regeneration, 441–443
- Guanine (G), 61, 481–482
- Guanosine diphosphate (GDP), 15, 405–406
- Guanosine triphosphate (GTP), 15
- Gum acacia, 7
- Gum Arabic, 7
- Gut microbiota modulation, 277
- H**
- Halimeda*, 204
- Halloysite nanotubes (HNT), 399
- Halogen polymers, 308–309
- Health care, nutraceutical compounds in, 97–99
- Haemophilus influenzae*, 274
- Heat shock protein, 297–298
- Heavy metals, 139
- Helicobacter pylori*, 173

- Hemagglutinin esterase (HE), 111
Hemicelluloses, 71–72, 125–126
 modification techniques for, 74f
Hemocyanins, 282
Hemolysis, 583–584
Heparin, 54, 54f, 126–127, 166, 173, 505
Heparin sulfate (HS), 505
Heparin/heparan sulfate, 505
Hepatic cancer, proteins and nucleic acid in, 261–262
Hepatocellular carcinoma cells (HCC), 593
Heptoses, 5
Hericium erinaceus, 251
Herpes viruses, 56
Heterogeneous biocatalysts, 531–532
Heterogeneous nuclear ribonucleoprotein (hnRNP F), 235–236
Heterogeneous nuclear ribonucleoprotein K (hnRNP K), 235–236
Heteropolysaccharides, 5, 168–169
Hexoses, 5
Hyaluronic acid (HA), 409
Hibiscus rosa-sinensis, 342
High branched isoterpenoid (HBI), 204
High Performance Gel Permeation Chromatography (HPGPC), 244–249
High performance liquid chromatography (HPLC), 254
High-performance anion-exchange chromatography (HPAECPAD), 256
Hippophaerhamnoides L.
 See Seabuckthorn
 (*Hippophaerhamnoides* L.)
Hirustella sinensis, 256
Histone deacetylases (HDACs), 277
Histones, 13
Homer/vesl proteins in CNS injury, 220–222
Homopolysaccharides, 5
Hordeum vulgare, 236–237
Host defense peptides, 307–308
Hot buffer soluble solids (HBSS), 249
Human adipose-derived stem cells (hADSCs), 385
Human immunodeficiency virus (HIV), 56, 361
Humira. See Adalimumab
HUS. See Scoville Heat Units (HUS)
Hyaluronan, 505–506
Hyaluronate, 506
Hyaluronic acid (HA), 126–127, 166, 168–169, 169f, 174, 406, 430, 505
 injectable hydrogels on, 410t
Hybrid carbohydrates, 566–567
 tacrine-(carbohydrate-derived) hybrids, 567f
Hydralazine, 342–343
Hydro distillation (HD), 265–266
Hydrogels, 394, 445–446, 465–466, 586, 598
 for drug delivery, 585–592
 injectable hydrogels as drug delivery systems, 586–588
 oral hydrogels as drug delivery systems, 588–592
 fabrication of, 466–467
 hydrogel-based microparticles as drug delivery systems, 589–591
 hydrogel-based nanoparticles as drug delivery systems, 591–592
Hydrogen, 4
 bonding, 463
Hydrogen peroxide (H₂O₂), 25–26
Hydrolyzable polyphenols, 152
Hydrophilic L-amino acids, 26–27
Hydrophilic/hydrophobic balance, 311–312
Hydrophobic interactions, 463–464
2-hydroxy-3-trialkylammonium propyl, 42
Hydroxyapatite (HA), 381–382, 395, 596–597
Hydroxypropyl cellulose (HPC), 396–397
Hydroxypropyl methylcellulose (HPMC), 342
Hyperkalemia, 327
Hyperlipoproteinemia, 10
Hyperphosphatemia, 327–328
Hypnea pannosa, 205
Hypodermis, 597–598
Hyriopsis cumingii, 146
Hyrtios erectus, 204–205
- I**
Iminoalditols, 554
Iminosugars, 554–561, 555f, 556f
 DNJ and 1-DNJ-related drugs, 557f
 fused oxazolidinone iminosugars, 561f
 piperidine iminosugars inhibitors, 556f
 potent glycosidase inhibitors
 pyrrolidine-based iminosugars, 559f
 synthetic tricyclic benzimidazole-iminosugars, 561f
Immature GFs, 419
Immobilization based on enzyme adsorption, 531–532
Immobilized Rapidase C80, 540
Immunoglobulins (Ig), 273–274
Immunohistochemical assay, 254
Immunomodulation, 273–274
 biomolecules, and applications, 274–275
Immunomodulatory approach, 115–116, 273
 for different health conditions, 274f
immunomodulation, 274
 lipids, 277–280
 polysaccharides, 275–277
 proteins, 280–282
Immunostimulatory effect of carbohydrates, 125
In situ polymerization, 468
In vitro biological testing, 493–494
In vivo testing, 472
Indolizidines, 559–560
 alkaloids of, 560
Infectious diseases, 306
Inflammation, 273, 289
Inflammatory bowel diseases (IBD), 274–275
Inflammatory cell activation sites, 139
Inflammatory cytokines, 281–282
Infliximab, 274–275
Influenza A virus, 317
Infra-red analysis (IR analysis), 244–249
Injectable hydrogels, 404
 as drug delivery systems, 586–588
 drug-loaded, 403–411
Injection-gelation method, 467
Inonotus obliquus. See Chaga mushroom (*Inonotus obliquus*)
Insulin-like growth factor 1 (IGF-1), 442
Insulin-like growth factor 2, 235–236
Insulin-loaded transferosomes, 364–367

- Intelligent packaging, 322
 Intelliject™, 620–622
 Interfering RNA (RNAi), 61
 Interferon (IFN- γ), 254
 Interleukin (IL)
 IL1, 102–103
 IL-1 β , 123–124
 IL-2, 254
 IL6, 102–103, 123–124
 IL-12, 274–275
 Interpenetrating polymeric network (IPN), 345
 Intestinal epithelial cells (IECs), 277
 Intravenous toxicity, 583–584
 Invertases, 529–530
 Inverting enzymes, 552–553
 Inverting glycosidases, 552–553
 Ionic gelation technique, 343–344
 Ionic interaction, 531–532
 Ionic polymerization, 309–310
 Irgasan (IRG), 402
 Irradiation of microwave, 230–232
 Irritable bowel syndrome (IBS), 289
 Isoascorbic acid, 321
 Itraconazole-loaded pectin-based nanoparticles, 345–347
- J**
Juglans mandshurica, 236–237
 Juvenile Rheumatoid arthritis, 281–282
- K**
 k-carrageenan, 384–385, 409
Kaempferia rotunda, 259
 Kalimate, 327
 Kayexalate, 327
 Keratan sulfate (KS), 505
 Keratins, 166, 175, 425–426, 444, 505
 biomacromolecules, 444
 extraction processes of, 427f
 keratin-based hydrogels, 352
 keratin-based nanoparticle, 190
 keratin-chitosan, 182–183
Klebsiella pneumonia, 206
 Korsmeyer-Peppas kinetic model, 396–397
- L**
 L-amino acid oxidases (LAOs), 25–28, 29t
Lablab purpureus, 149–150
Lactobacillus, 289–290
 L. brevis, 509–510
 Lactoferrin (Lfcn), 176–177
 lactoferrin-oleic acid, 185
 Lactonases, 32–33
 Lactose, 289–290
 Lactoseries, 223
 Lactosylceramide, 276
Laminaria
 L. digitata, 183–184
 L. hyperborea, 183–184
 L. japonica, 147–148, 183–184
 Laminin, 511
 Lapacho tree (*Tabebuia avellanedae*), 244
 Layer-by-layer assembly (LbL assembly), 468
 Leber neuropathy, 612–614
 Lecithins, 10
 Leishmaniasis, 319
Leuconostoc mesenteroides, 509–510, 537
 Leukocytes, 58–59
 Leukotrienes, 278–279
 Levofloxacin (LEVO), 402
 Lewis lung carcinoma (LLC), 255
 Lichenan. *See* Lichenin
 Lichenin, 56
 Light at night (LAN), 617
 Lignin, 71–72, 72f, 462
 chemical modification of, 76t
 enzymatic modification of, 77t
 LIN28 gene, 235–236, 300
 Lincosamides, 307–308
Lindra thalassiae, 205
 Linoleic acid (LA), 120, 179–180, 263–264
Linum usitatissimum, 236–237
 Lipases, 529–530, 541
 Lipid nanoparticles (LNPs), 60, 234, 279–280
 Lipid(s), 3, 9–11, 23, 53, 60–61, 230, 262–269, 277–280, 305, 582–583
 as antidiabetic agents, 233–234
 as antimicrobial agents, 170–171
 nucleic acid, 171–172
 phospholipid, 170
 sterol, 170–171
 triglyceride, 170
 basic functions of, 12t
 brain cancer, 265–266
 breast cancer, 264–265
 colon cancer, 263–264
 compound or conjugate, 10
 derived, 10–11
 drug delivery using, 359–367, 366t
 drug delivery-based on lipids, 60–61
 function, 339–340
 immunomodulatory effect of lipids, 278–280
 lipid-based drug delivery systems, 482–484
 liver cancer, 266
 as nutraceuticals, 119–123
 omega-3 PUFAs role in some disorders, 121–123
 polyunsaturated fatty acids, 120–121
 psychiatric and neurological disorders, 122f
 others, 267–269
 ovarian cancer, 266–267
 peroxidation, 27, 225–226
 role on nervous system, 224–225
 phospholipids, 224–225
 simple, 10
 skin cancer, 267
 Lipopeptides, 307–308
 Lipoproteins, 10, 13
 Liposomes, 401–402, 592
Listeria monocytogenes, 166, 401–402
 Liver cancer, lipids in, 266
 Living cells, 491–492
 Local fungal infections, 318
 Locked nucleic acid (LNA), 593
 Long chain fatty acid, 298
 Low molecular weight (LMW), 385
 Low-density lipoprotein cholesterol (LDL), 324–326
 Lung cancer, carbohydrates in, 255–257
 Lutein (C₄₀H₅₆O₂), 106, 458
 Luteolin, 104
 Lycopene, 105
 Lymphocytes, 274
Lynigabya confervoides MK012409, 259–260
 Lysostaphin, 25, 28–32, 29t
- M**
Macrocystis pyrifera, 156
 Macrogels, 586
 Macrolides, 307–308
 Macromolecules, 53–54, 567–570.
 See also Biological macromolecules
 as antioxidants, 152–156

- nonextractable polyphenols as antioxidants, 156
 polysaccharides as antioxidants, 152–155
 proteins as antioxidants, 155–156
 in biomedical applications, 583–584
 multivalents, 567–569
 polysaccharides, 569–570
 synthesis of, 63–64
 in targeted drug delivery, 584–585
 on tissue engineering, 593–599
 Macrophages, 274
 Macular pigment (MP), 106
 Magnetic chitin nanofiber composites (MCNCs), 533
 Magnetite nanoparticles, 179
 Maillard reaction, 464
 Maltodextrin, 289–290
 Maltose, 289–290
Malus micromalus, 146
 Mannitol, 54, 55f, 289–290
 Mannose receptors (Mr), 282
 Marine fungi, 148
 Marine-derived polysaccharides, 147–149
Massonia pustulata. See Beetle (*Massonia pustulata*)
 Mechanical crushing method, 468
 Medical therapy, 98
 Medicinal interest of carbohydrates, 550–551
 Medium chain fatty acid, 298
 MelodieTM, 620–622
 Meroterpenoids, 205–206
 Mesenchymal stem cells (MSCs), 401–402, 444–445
 Messenger RNA (mRNA), 16–17, 62, 483, 584
 Metallo- β -lactamaselike lactonase (MLL), 25
 Metalloproteins, 13
 Metaproteins, 13
 Metformin, 229–230
 Methacryloyl chitosan (MC), 407
 Methotrexate (MTX), 608–609
 Microalgae, 203
 antimicrobial peptides, 203
 Microalgal polysaccharides, 148
 Microcapsules, fabrication of, 467–468
Micrococcus luteus, 31
 Microemulsion/emulsion-templating methods, 468–469
 Microencapsulation, 590
 Microgels, 586
 Microorganisms, carbohydrates with nutraceutical activity from, 128
 MicroRNAs (miRNAs), 62, 116, 260–261
 Migalastat, 557–558, 557f
 Miglitol, 557–558, 557f
 Miglustat, 557–558, 557f
Millettia pulchra, 253–254
 Minerals, 140–141, 471
 Minimum inhibitory concentration (MIC), 316
 miR-22, 261
Misgurnusanguilli caudatus, 146
 Mitochondria peroxisomes, 139
 Mitochondrial DNA (mtDNA), 610–611
 Mitochondrial gene therapy, 610–616
 mitochondrial mutations, 611–612
 mitochondrion, 611
 targeting mitochondria, 612–616
 Mitochondrial membrane potential (MMP), 251–252
 Mitochondrial mutations, 611–612
 Mitochondrion, 610–611
 Mitomycin-C, 351
 Modification of carbohydrate biological macromolecules, 73–86
 cellulose
 chemical modification of, 75t
 enzymatic modification of, 76t
 physical modification of, 74t
 chitin/chitosan
 chemical modification of, 80t
 enzymatic modification of, 84t
 physical treatments for, 80t
 classification of modification, 73f
 hemicellulose, modification techniques for, 74f
 lignin
 chemical modification of, 76t
 enzymatic modification of, 77t
 Molecular assembly methods, 469
 Molecular interactions, 462–464
 covalent interactions, 464
 electrostatic interactions, 463
 hydrogen bonding, 463
 hydrophobic interactions, 463–464
 Molecular weight (MW), 36–37, 273–274, 312, 493–494
Momordica
 M. charantia, 236–237
 M. cymbalaria, 236–237
 M. dioica, 236–237
 Monoclonal antibodies (mAb), 58–59, 280, 281t
 first generation, 59
 fourth generation, 60
 second generation, 59
 third generation, 59–60
 Monocutaneous Leishmaniasis, 319
 Monomethyl (MM), 319
 Monophosphoryl Lipid A, 279–280
 Monosaccharides (Ms), 4–5, 167, 289–290, 548
 Monoterpenes, 243
 Monoterpenoids, 203–204
Moringa oleifera, 236–237
 MP optical densities (MPOD), 106
 mRNA, 255
 technologies, 584–585
 Mucoadhesive nonwoven fibers, 396
 Mucopolysaccharides, 505
 Multidrug resistant microbes (MDR microbes), 165
 Multifunctional natural antioxidants, 159
 Multilamellar vesicles, 592
 Multivalents, 567–569
 pyrrolidine iminosugars, 568f
Muricauda olearia, 32–33
 Mutagenicity, 583–584
Mycobacterium tuberculosis, 559
Myrica gale L., 263
N
N,N,N-trimethyl chitosan (TMC), 42
N-(2-hydroxypropyl)methacrylamide copolymer, 306
N-butyl-DNJ, 557
N-vinylpyrrolidone, 305
N. sativa essential oil nano emulsion (NSEO-NE), 264–265
 Nanoassemblies, 448–449
 Nanofiber scaffolds, 447
 Nanogels, 586
 Nanohydroxyapatite (n-HA), 595–596
 Nanomaterials, 591, 607–608
 Nanoparticles (NPs), 395, 439, 448–449
 fabrication of, 468–469
 Nanoparticles from chitosan (CsNP), 593
 Nanotechnology, 479, 607–608

- Nanotechnology (*Continued*)
 based antimicrobial macromolecule, 185–190
 alginate-based nanocomposite, 187
 cellulose based nanocomposite, 187–189
 chitosan based nanocomposite, 185–187
 collagen based nanocomposite, 190
 gelatin based nanocomposite, 189–190
 keratin-based nanoparticle, 190
 oleic acid based nanoparticle, 190
 based macromolecule composites, 166
- Naringenin, 104
- National Program for Science and Technology Development Plan, 53–54
- Natural antioxidants, 320
- Natural bioactive micromolecular compounds, 141
- Natural bone mineral (NBM), 426
- Natural fatty acids, 262–263
- Natural immunomodulatory proteins, 282
- Natural killer cell (NK cell), 274
- Natural polymers, 305
 in TE, 508–511
 carrageenans, 509
 cellulose, 508
 dextrans, 509–510
 elastin, 511
 fibronectin, 511
 gellan, 510
 laminin, 511
 pullulans, 510–511
 starch, 508–509
- Natural surfaces, 308
- Naturally derived biological macromolecules, 3–4
- Nelumbo nucifera*, 141
- Nephilia clavipes*, 506–507
- Nervous system, carbohydrates role on, 223
- Neural development, glycan role in, 224
- Neuraminidase (NA), 565
- Neurodegenerative diseases, 225
- Neurological disorders, 219
- Neutrophils, 274
- Nigella sativa* L. (NS), 264–265
- No methyl (NM), 319
- Non-mRNA sequences, 116–117
- Non-small cell lung cancer/carcinoma (NSCLC), 262, 268
- Noncoding DNA (ncDNA), 116
- Noncoding ribonucleic acid, 300
- Noncommunicable diseases (NCDs), 98
- Nonextractable polyphenols, 152
 as antioxidants, 156
- Nonspecific-action immunomodulators, 274
- Nonviral vectors, 608–610
- Norepinephrine, 222
- Nortropanes, 559–560
- Nuclear factor, interleukin 3 regulated (NFIL3), 617
- Nuclear factor-kB (NF-kB), 102–103
- Nuclear magnetic resonance (NMR), 244
- Nucleic acid(s), 3, 14–17, 23, 61–63, 230, 289, 305, 582–583
 as antidiabetic agents, 237–238
 as antimicrobial agents, 171–172
 biological macromolecules for delivery, 482–488
 carbohydrate-based drug delivery systems, 486–488
 lipid-based drug delivery systems, 482–484
 protein-based drug delivery systems, 484–486
 for cancer therapy, 258–262
 colon cancer, 259
 colorectal and breast cancer, 259–261
 hepatic cancer, 261–262
 NSCLC, 262
- DNA, 15–16
 drug delivery using, 355–359
 nucleosides, 15
 nucleotides, 15
 as nutraceuticals, 112–119
 in biomedicine, 112–119
 DNA/RNA functional sequence, 116–119
 DNA/RNA nanostructures, 113–116
 perspectives, 119
- RNA, 16–17
 role in gastrointestinal system, 300
 structure and functions, 480–482
- Nucleoproteins, 13
- Nucleosides, 15
- Nucleotides, 14–15, 481–482
- Nutraceuticals, 97–98, 470
 alkaloids, 99–102
 carbohydrates as, 124–129
 future views, 107
 history of applications of nutraceutical compounds in health care, 97–99
- lipids, 119–123
 nucleic acids and nutraceutical properties used in biomedicine, 112–119
 phenolic compounds, 102–104
 potential use of bioactive lipids in cancer stem cells and coronavirus disease, 123–124
 proteins and peptides with biological activity of medical interest, 107–112
 terpenes, 105–107
- Nutrients, 455–458
 bioactive molecules, 471–472
 biological macromolecules for delivery, 458–462
 glycoproteins, 461–462
 polysaccharides, 459–461
 proteins, 461
 proteoglycans, 461–462
 co-encapsulation of, 471
 delivery systems based on biological macromolecules, 465–471
 applications, 469–471
 composition and structure, 465–466
 fabrication, 466–469
 properties, 469
 health benefits and limitations of, 457f
 molecular interactions, 462–464
 oil-soluble nutrients, 458
 retention and release mechanisms, 464–465
 substances in nutrient delivery systems, 459f
 in vivo testing, 472
 water-soluble, 456–457
- Nutrition, 97, 120–121
- Nylon-3 polymers, 319

- O**
- Ocimum kilimandscharicum*, 266–267
- Odontella aurita*, 148
- Oils, 10
- oil-soluble nutrients, 456, 458
- Oleic acid, 185
- Oleic acid based nanoparticle, 190
- Oleylethanolamide (OEA), 123
- Oligomers, 479–480
- Oligonucleotides, 53, 61–63, 584–585
- therapeutics based on, 61–63
 - antisense oligonucleotides, 62
 - aptamer, 63
 - siRNA, 62–63
- Oligosaccharides (OS), 4–5, 168, 289–290. *See also* Polysaccharides (PS)
- Omega-3 fatty acid (O3FA), 210–211, 298
- Omega-3 polyunsaturated fatty acids, 470
- in disorders, 121–123
- Omega-6 fatty acids, 278–279, 298
- Ophiopogon japonicus*, 257–258
- Optimal cancer chronotherapy, 622
- Oral drug administration, 582
- Oral hydrogels as drug delivery systems, 588–592. *See also* Injectable hydrogels
- hydrogel-based microparticles as drug delivery systems, 589–591
 - hydrogel-based nanoparticles as drug delivery systems, 591–592
- Oral toxicity pyrogenicity, 583–584
- Oregano (*Origanum vulgare*), 243
- Organocatalytic living ring-opening polymerization, 306
- Organotin polymers, 317–318
- Origanum vulgare*. *See* Oregano (*Origanum vulgare*)
- Oseltamivir, 317
- Osteoarthritis, 439–440
- Osteoblasts, 596
- Osteocalcin (OCN), 385
- Osteoclasts, 596
- Osteopontin (OPN), 385
- Osteoporosis, 439–440
- Ostrinia furnacalis, 565–566
- Ovarian cancer, lipids in, 266–267
- Overhydroxylation, 439–440
- Oxidative stress, 139
- Oxygen, 4
- P**
- P407 hydrogels, 588
- Paclitaxel (PTX), 359, 622–623
- Paclitaxel-loaded polymeric nanoparticles (PTX-NPs), 622–623
- Padinasanctaerucis*, 147–148
- Panax ginseng*, 292–294
- Pancreatic cancer, carbohydrates in, 257–258
- Paracetamol suspensions, 341–342
- Parageobacillus caldoxylosilyticus*, 35
- Parasites, 319
- Parkinson's disease (PD), 3–4, 219, 612
- Passive polymers, 315
- Pasteur, L. (father of microbiology), 307
- Pathogen-associated molecular patterns (PAMPs), 276
- Pathogenic microbes, 165
- Pathogenic microorganisms, 305–306
- Patiromer, 327
- Pavlova viridis*, 148
- Pectins, 7, 8f, 459–460
- for enzyme immobilization, 539–540
- Penicillin G acylase, 529–530
- Penicillins, 99
- Penicillium*
- P. fellutanum*, 559
 - P. italicum*, 540
- Penicillium*, 204
- Pentoses, 5
- Peptides, 14, 53, 56–58, 203, 209–210, 581–582
- alkaloids, 99
 - with biological activity of medical interest, 107–112
 - drug delivery using, 349–355, 356t
 - therapeutics based on peptides, 57–58
- Peptones, 14
- Periploca laevigata*, 146
- Permeability of glycoprotein (p-gp), 234
- pH-dependent polymers, 591
- Phaeodactylum tricornerutum*, 212
- Phalaris canariensis*, 236–237
- Phallaidin, 402
- Pharmaceutical nanotechnology, 591
- Phaseolus vulgaris*, 236–237
- Phenolic compounds, 102–104
- anthocyanins, 103
 - catechins, 104
 - curcumin, 102–103
 - luteolin, 104
 - naringenin, 104
 - quercetin, 103
 - resveratrol, 103
- Phenolics, 207–208
- Pholidota chinensis*, 250–251
- Phosphate buffered saline (PBS), 447
- Phosphobetaine, 315
- Phospholipids, 10, 170, 171f, 224–225
- polymers, 315
- Phosphoproteins, 13
- Phosphotidic acids, 10
- Phycobiliproteins, 151
- Phycocyanin, 151
- Phycoerythrin, 151
- Phycoerythrocyanin, 151
- Phytophthorainfestans, 172
- Pituranthos tortuosus*, 267
- Plants
- carbohydrates from, 125
 - plant-derived polysaccharides, 141–146
 - plant-derived proteins, 149–150
- Plasmalogens, 10
- Plasmid DNA (pDNA), 483, 593, 609–610
- Plasmodium*
- P. falciparum*, 205–206, 319
 - P. knowlesi*, 319
 - P. malariae*, 319
 - P. ovale*, 319
 - P. vivax*, 319
- Platelet-derived growth factor (PDGF), 384
- Pleurotus sajor-caju*, 36–37
- Plocamium cornutum*, 205
- Plumula nelumbinis*, 141
- Pluronic F-127, 398
- Polar lipids, 120
- Polo-like kinase 1 (PLK1), 117
- Poloxamines, 445–446
- Poly (amidoamine) (PAMAM), 592, 609
- Poly (caprolactone) (PCL), 395
- Poly (lactide-co-glycolide) (PLGA), 595–596
- Poly (vinyl alcohol) (PVA), 395
- Poly *N*-isopropyl acrylamide-co-acrylic acid (PNIPAM), 396, 587

- Poly(1-naphthylamine-azobenzene) (PNA-AB), 319–320
- Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), 446–447
- Poly(aniline-azobenzene) (PANI-AB), 319–320
- Poly(dimethylacrylamide), 315
- Poly(dimethylsiloxane), 315
- Poly(epichlorohydrin-co-ethylene oxide) (PECO), 401–402
- Poly(ethylene glycol) dimethacrylate (PEGDMA), 431
- Poly(ethylene oxide) (PEO), 396
- Poly(ethyleneimine), 316
- Poly(lactic acid) (PLA), 402
- Poly(lactic-co-glycolic acid) (PLGA), 399, 431, 446–447, 593
- Poly(luminol-azobenzene) (PLu-AB), 319–320
- Poly(*N,N*-dimethylaminoethyl methacrylate) (PDMAEMA), 312–313
- Poly(*N*-vinylpyrrolidone), 315
- Poly(*o*-phenylenediamineazobenzene) (PPd-AB), 319–320
- Poly(vinylpyrrolidone) (PVP), 396
- Poly(ϵ -lysine) (EPL), 401
- Polyampholytes, 315
- Polydatin (PD), 255
- Polyethylene glycol (PEG), 232–233, 315, 421, 612–614
- Polyethyleneimine (PEI), 308–309, 609–610
- PEI-based nanosystem, 612–614
- Polyglycerol sebacate-polyethylene glycol methyl ether methacrylate (PGSPEGMEMMA), 587
- Polygonatum cyrtonema* Hua (PCH), 249
- Polygonatum sibiricum*, 146, 255
- Polygonatum sibiricum* polysaccharides (PSPs), 255
- Polygonum cuspidatum*, 255
- Polyguanidines, 316–317
- Polyketide, 210
- Polymer sequestrants, 324–328
- Polymeric architecture, 313
- Polymeric bile acid sequestrants, 324–326
- Polymeric biocides, 308
- Polymeric composites, 309, 430
- Polymeric polyphenols, 152
- Polynucleotides, 496
- Polyols, 289–290
- Polysaccharide derivative from wild *R. griseocarnos* (PRG1–1), 249–250
- Polysaccharides (PS), 3–9, 55, 141–149, 208–209, 275–277, 289–290, 459–461, 548, 569–570, 585–586
- alginate, 460
- animal-derived, 146–147
- antimicrobial activity of, 172–174
- alginate, 173
- cellulose, 173
- chitosan, 172
- chondroitin, 173–174
- heparin, 173
- hyaluronic acid, 174
- as antioxidants, 152–155
- bacterial and fungal, 149
- carrageenan, 460
- combinations for GFs delivery, 429–430
- derived from herbs in nature, 126*t*
- drug-loaded polysaccharides-based ESF, 395–400
- gut microbiota modulation, 277
- immunomodulatory, 275–277
- lyases, 551
- marine-derived, 147–149
- pectin, 459–460
- plant-derived, 141–146
- polysaccharide-based biomaterials, 581–582
- polysaccharide-based materials for GFs delivery, 427–429
- polysaccharide-polysaccharide composites, 433
- role in extracellular membrane, 124–125
- sources and functions of, 9*t*
- starch, 460–461
- Polysaccharides extracted from *Inonotus obliquus* (IOP), 256
- Polyunsaturated fatty acids (PUFAs), 120–121, 121*t*, 210–211
- from algae, 210–213
- precursors and types of, 121*f*
- Polyurethane (PU), 315–316, 395
- Polyvinyl alcohol (PVA), 423, 598
- Polyzwitterions, 308–309
- Portieria hornemannii*, 205
- Procambarus clarkia*, 252–253
- Proinflammatory cytokines, 276–277
- Proinflammatory mediators, 292–294
- Prolamins, 13
- Propidium iodide (PI), 249
- Protoctia brevitarsis* L (PBL), 263
- Protamines, 13
- Proteases, 529–530, 541
- Protein Data Bank (PDB), 24
- Protein(s), 3–4, 11–14, 12*f*, 23, 53, 58–60, 149–152, 230, 280–282, 305, 461, 581–583
- algal-derived proteins, 151–152
- animal-derived proteins, 150–151
- as antidiabetic agents, 235–237
- antimicrobial activity of, 175–177
- collagen, 175
- fibrin, 176
- gelatin, 175
- keratin, 175
- lactoferrin, 176–177
- soy protein, 176
- as antimicrobial agents, 169
- types and functions, 170*t*
- as antioxidants, 155–156
- with biological activity of medical interest, 107–112
- for cancer therapy, 258–262
- colon cancer, 259
- colorectal and breast cancer, 259–261
- hepatic cancer, 261–262
- NSCLC, 262
- in CNS injury, 219–220
- amyloid-beta and tau protein, 219–220
- conjugated, 13
- derived, 13–14
- drug delivery using, 349–355, 356*t*
- drug-loaded protein-based ESF, 401–403
- engineering approaches, 529
- expression, 614–616
- immunomodulatory, 280–282
- plant-derived proteins, 149–150
- protein-based composite for GFs delivery, 430–432
- protein-based drug delivery systems, 484–486
- protein-based materials for GFs delivery, 425–427

- protein-polysaccharide composites
for GFs delivery, 432–433
- protein-polysaccharide-based
nanoparticles, 592
- role in gastrointestinal system,
295–298
- simple, 12–13
- therapeutics based on proteins,
58–60
- mAb, 58–59
- protein-based therapeutics, 58
- Proteoglycans, 13, 461–462
- Proteoses, 14
- Pseudoalteromonas bacteriolytica*, 205
- Pseudomonas*, 173–174
- P. aeruginosa*, 313
- P. elodea*, 510
- Pseudosugars, 561–562
- Pullulans, 487–488, 510–511
- Punica granatum*, 244
- Pure zein fibers, 401
- Purines, 481–482
- bases, 582–583
- Pyrimidines, 481–482
- bases, 582–583
- Pyrrrolidizines, 559–560
- alkaloids of, 560
- Q**
- Quaternary phosphonium salts (QPS),
315
- Quercetin, 103
- Quercus brantii*. See Zagros oak
(*Quercus brantii*)
- Quorum quenching (QQ), 32–33
- Quorum sensing (QS), 32–33
- R**
- Radix astragali*, 141–146
- Raffinose, 168, 168f, 289–290
- Reactive oxygen species (ROS), 27,
55–56, 105, 139, 187, 249–250,
276
- Reactive oxygen/nitrogen species
(ROS/RNS), 139
- Real-time quantitative reverse
transcription PCR (qRT-PCR),
255, 258
- Receptor-related orphan receptor
(ROR), 617
- Recombinant human bone
morphogenetic protein-2
(rhBMP-2), 443
- Red alga (*Gloiopeltis furcata*), 148
- Regenerative medicine, 393
- Resistant starch (RS), 460–461
- Resveratrol, 103
- Retaining enzymes, 552–553
- Retaining glycosidases, 552–553
- Retention and release mechanisms,
464–465
- Retino-tectal system, 223
- Retinoblastoma (RB), 619–620
- Reversible addition-fragmentation
chain transfer polymerization
(RAFT), 309–310
- Rhamnose (Rha), 254
- rhBMP2, 401–402
- Rheumatoid arthritis, 281–282
- Rhodophyceae gelidium*, 496–497
- Riboflavin (C₁₇H₂₀N₄O₆), 456–457
- Ribonucleic acid (RNA), 3, 16–17, 61,
171–172, 230, 480, 582–583
- functional sequence, 116–119
- CRISPR, 117–119
- gene therapy, 117
- non-mRNA sequences, 116–117
- nanostructures, 113–116
- biosensing, 113–114
- drug delivery, 114–115
- immunomodulatory, 115–116
- nanotechnology, 358
- Ribose, 61
- Ribosomal RNA (rRNA), 16–17
- Rifampicin, 355
- Rimantadine, 317
- Ring-opening metathesis
polymerization (ROMP), 306,
309–310, 323–324
- RNA interference (RNAi), 584–585
- RNA-induced silencing complex
(RISC), 62
- Roburin D (RobD), 566–567
- Rosmarinus officinalis* L., 266
- Runt-related transcription factor 2
(run-2), 385
- Russula griseocarnosa*, 249–250
- S**
- S-lac type lectins, 222–223
- Saccharomyces*, 289–290
- S. cerevisiae*, 258, 563
- Salacinol, 564–565
- Salmonella*, 176–177
- S. typhimurium*, 166
- Salvia officinalis*, 267
- “Same centered” approach, 311–312
- Sarcinochrysis marina*, 148
- Sarcodia ceylonensis*, 148
- Sargassum*
- S. fluitans*, 147–148
- S. macrocarpum*, 205–206
- S. wightii*, 232
- Sargassum henslowianum*. See Brown
alga (*Sargassum henslowianum*)
- Saturated fatty acid, 298
- SBPW3, 258
- Scaffolds, 446–447, 507–508
- Scanning electron microscope (SEM),
251
- Scenedesmus* sp., 252
- Schinus molle* L., 264
- Schinus terebinthifolius*, 264
- Scoville Heat Units (HUS), 101
- Scutellaria barbata*, 258
- Scytosiphonolomentaria*, 156
- Seabuckthorn (*Hippophaerhamnoides*
L.), 146
- Seaweeds, 210
- Second generation monoclonal
antibodies, 59
- Second-line defense antioxidants,
140–141
- Secondary derived proteins, 14
- Secondary metabolites (SM), 97–99,
107
- with nutraceutical activity, 108f
- “Segregated monomer” approach,
311–312
- Selectivity index (SI), 264
- Self-assembly methods, 468
- Self-healing polymers, 315
- Sensitization, 583–584
- Sensory organs, 223
- Serotonin (5-HT), 222
- Sesquiterpenoids, 203–204
- Sesterterpenoids, 203–204
- Severe acute respiratory syndrome
(SARS-CoV-2), 123, 306
- Shear’s polysaccharide, 275
- Shearing-gelation method, 467
- Short chain fatty acids (SCFA), 177,
277, 298
- Sickle cell disease (SCD), 119
- Silk, 506–508
- Silk fibroin-based patches (SF-based
patches), 401–402
- Silver nanoparticles (Ag NPs),
173–174, 179

- Simvastatin (SIM), 596
- Single nozzle electrospinning technique, 395
- Skin cancer, lipids in, 267
- Skin regeneration, 442
- Skin substitutes development, 597–599
- Skin tissue replacement, 598
- Small interfering RNA (siRNA), 62–63, 116–117
- Snake venoms (SV), 25
- Snigella dysentri*, 206
- Sodium alginate (SA), 398
- Sodium bicarbonate (NaHCO₃), 405–406
- Sodium erythorbate, 321
- Solid lipid nanoparticles, 362
- Solid-liquid phase separation, 443
- Sorbitol, 289–290
- Soy protein, 166, 176
- Soy protein isolated (SPI), 399
- Sphingomyelins, 10
- Spider silk, 507
- Spidroin, 506–508
- Sponges, 445–446
- Spray drying, 468
- Stage specific embryonic antigen 1 (SSEA1), 224
- Staphylococcus*, 173–174
S. aureus, 6, 27, 149, 166, 205–206, 313
S. epidermidis, 149, 176–177
S. simulans, 28–30
- Starch, 5–6, 6f, 460–461, 508–509
- Steroids, 11, 206–207
- Sterols, 11, 170–171, 171f
- Stigma maydis*, 244
- Stimulator of IFN genes (STING), 276–277
- Streptococcus*, 289–290
S. mutans, 509–510
S. pneumoniae, 42
- Streptogramins, 307–308
- Streptomycesnojiriensis*, 554–555
- Stromal cell-derived factor (SDF), 430–431
- Strontium (Sr), 383–385
- Structure-guided technologies, 529
- Structure–activity relationship (SAR), 23–24
 chitosan as bioactive polysaccharide, 36–42
 enzymes as bioactive proteins, 24–36
- Sucrose, 167–168, 168f, 289–290
- Sulfate, 505
- Sulfobetaine, 315
- Sulfur nanoparticles, 191
- Sulphamethoxazole suspensions, 341–342
- Sulphated polysaccharide of *A. cinnamomea* (SPS), 257
- Sulpholipids, 10
- Supercritical fluid extraction approach, 230–232
- Superoxide dismutase (SOD), 140–141
- Superworm (*Zophobasemorio*), 146
- Supramolecular chemistry, 549
- Surface erosion mechanism, 465
- Survivin intertransfer RNA (siRNA), 593
- Sweet potato glycoproteins (SPG), 259
- Swelling mechanism, 465
- Synthesis of macromolecules, 63–64
- Synthetic antioxidants, 320
- Synthetic drugs, 229–230, 243
- Synthetic macromolecules
 with antibacterial activity, 313–317
 with antifungal activity, 318–319
 with antimicrobial activity, 306–320
 with antiparasitic activity, 319–320
 with antiviral activity, 317–318
 with biological activity, 305
 polymer sequestrants, 324–328
 synthetic macromolecules with antioxidant activity, 320–324
- Synthetic polymers, 305, 319, 492
- Synthetic surfaces, 308
- Systemic fungal infections, 318
- Syzygium aromaticum*. See Clove buds (*Syzygium aromaticum*)
- T**
- T helper cells (Th cells), 280
- T regulatory cells (Tr cells), 280
- T-cell receptors (TCR), 275–276
- Tabebuia avellanadae*. See Lapacho tree (*Tabebuia avellanadae*)
- Tannins, 566
- Targeted drug delivery
 biomaterials as, 585–593
 macromolecules in, 584–585, 585f
- Targeting mitochondria, 612–616
 gene and protein expression, 614–616
- Tau protein, 219–220
- Temperature-sensitive hydrogels, 588
- Terfaira occidentalis*, 236–237
- Terpenes, 105–107, 106f
 β -Carotene, 105–106
 lutein, 106
 lycopene, 105
 zeaxanthin, 107
- Terpenoids, 203–206
 isomers of, 205f
- Terpyridine, 173
- 2-tert-butylhydroquinone (TBHQ), 321
- Tetracycline, 307–308
 HCl, 397–398
- Tetraterpenoids, 203–204
- Tetroses, 5
- Theobroma cacao*, 236–237
- Theobromine, 101–102
- Therapeutic(s)
 based on carbohydrates, 55–56
 based on oligonucleotides, 61–63
 based on peptides, 57–58
 based on proteins, 58–60
 macromolecules, 273–274
- Therapies, biological macromolecules in, 53–54
- Thermotoga maritima*, 563
- Thiosugars, 564–566
 and inhibition constant for α -galactosidase from *Escherichia coli*, 565f
 isolated from *Salacia* species, 564f
- Third generation monoclonal antibodies, 59–60
- Third-line defense antioxidants, 140–141
- Three-dimensional porous scaffolds (3D porous scaffolds), 596–597
- Thyme essential oil (TEO), 401–402
- Thymine (T), 61, 481–482
- Tissue engineering (TE), 381, 393, 494
 BTE, 381–382
 drug-loaded electrospun fibers in, 394–403
 drug-loaded injectable hydrogels in, 403–411
 interaction and application in, 405f
 macromolecules on, 593–599
 skin substitutes development, 597–599
 wound management, 597
 scaffolds, 494

- Tissue regeneration, growth factors in, 441–443
- TMC. *See* *N,N,N*-trimethyl chitosan (TMC)
- Tolbutamide, 229–230
- Toll-like receptor (TLR), 276
- Toll-like receptor 4-mitogen-activated protein kinase/nuclear factor (TLR4-MAPK/NF- κ B), 255
- Transfer RNA (tRNA), 16–17
- Transferrin receptor 1 (TfR1), 624
- Transforming Growth Factor (TGF), 276–277
- Transmission electron microscope (TEM), 250–251
- Transport proteins, 339–340
- Tricalcium phosphate, 444–445
- Trichosanthes kirilowii*, 141–146
- Triglycerides, 120, 170, 171f
- Trimethylxanthine. *See* Caffeine
- Trioses, 5
- Tripolyphosphate, 448
- Trisaccharides, 5
- Trisodium trimetaphosphate, 399
- Triterpenoids, 203–204
- Triticum aestivum*, 236–237
- Trypanosoma cruzi*, 559
- Tryphenylphosphonium (TPP), 609–610
- Tumor necrosis factor (TNF), 274–275
TNF- α , 102–103, 254
- Tumor rejection antigens (TRA1), 224
- TUNEL assay, 256
- Turmeric (*Curcuma longa*), 149–150
- Type 1 diabetes, 229
- Type 2 diabetes, 229
- Type 3 diabetes, 229
- U**
- Udotea*, 204
- Ulcer, 289
- Ulcerative colitis (UC), 289–290
- effects of alkali soluble polysaccharide, 291f
- Ultraviolet (UV), 14, 586–587
- Ulva fasciata*. *See* Green alga (*Ulva fasciata*)
- Ulva* sp., 156
U. intestinalis, 148
U. lactuca, 148
- Ulvan, 3–4, 148, 385–386
- Uncharged polymers, 315
- Undaria pinnatifida*, 253
- Unsaturated fatty acids, 123
- Uracil (U), 61, 481–482, 582–583
- Uridine triphosphate (UTP), 15
- Ustekinumab, 274–275
- V**
- Vaccination, 115–116, 274
- Vaccines, 274
- Vascular endothelial growth factor (VEGF), 399, 441–442
- Very long chain fatty acid, 298
- Vigna*
V. angularis, 236–237
V. unguiculata, 236–237
- 2-vinylfuran, 305
- 2-vinylpyrrole, 305
- 2-vinylthiophene, 305
- Vipera ammodytes ammodytes*, 26–27
- Viruses, 317
- Visceral Leishmaniasis, 319
- Vitamin B₂. *See* Riboflavin (C₁₇H₂₀N₄O₆)
- Vitamin C. *See* Ascorbic acid (C₆H₈O₆)
- Vitamins, 470
- Volumetric Muscle Loss treatment (VML treatment), 425–426
- W**
- Water-soluble nutrients, 456–457
ascorbic acid, 456
riboflavin, 456–457
- Water-soluble polysaccharides, 146
- Waxes, 10
- Western blot, 255
- Whey protein, 461
- Wound dressing, antimicrobial agents on, 192–193
- Wound management, 597
- X**
- Xanthan for enzyme immobilization, 540–541
- Xanthan gum-konjac glucomannan (XG/KGM), 598–599
- Xanthomonas*
X. arboricola, 540–541
X. axonopodis, 540–541
X. campestris, 540–541
X. citri, 540–541
X. fragaria, 540–541
X. gummisudans, 540–541
X. juglandis, 540–541
X. phaseoli, 540–541
X. vascularium, 540–541
- Xenograft models of mice, 251–252
- Xylanases, 541
- Y**
- Y-box binding protein1 (YBX1), 235–236
- Yulangan polysaccharide (YLSPS), 253–254
- Z**
- Zagros oak (*Quercus brantii*), 141
- Zanamivir, 317
- Zeaxanthin, 107
- Zidovudine, 361
- Zika, 306
- ZnO nanoparticles (ZnO NP), 185–186
- Zopho basmorio*. *See* Superworm (*Zopho basmorio*)
- Zwitterionic polymers, 315
- Zwitterionic polysaccharides (ZPs), 275–276